<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Omega‐3 fatty acids for the treatment of dementia - Burckhardt, M - 2016 | Cochrane Library</title> <meta content="Omega‐3 fatty acids for the treatment of dementia - Burckhardt, M - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Omega‐3 fatty acids for the treatment of dementia - Burckhardt, M - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009002.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Omega‐3 fatty acids for the treatment of dementia" name="citation_title"/> <meta content="Marion Burckhardt" name="citation_author"/> <meta content="Martin Luther University Halle‐Wittenberg" name="citation_author_institution"/> <meta content="m.burckhardt@dgfw.de" name="citation_author_email"/> <meta content="Max Herke" name="citation_author"/> <meta content="Martin Luther University Halle‐Wittenberg" name="citation_author_institution"/> <meta content="Tobias Wustmann" name="citation_author"/> <meta content="Martin Luther University Halle‐Wittenberg" name="citation_author_institution"/> <meta content="Stefan Watzke" name="citation_author"/> <meta content="Martin Luther University Halle‐Wittenberg" name="citation_author_institution"/> <meta content="Gero Langer" name="citation_author"/> <meta content="Martin Luther University Halle‐Wittenberg" name="citation_author_institution"/> <meta content="Astrid Fink" name="citation_author"/> <meta content="Martin Luther University Halle‐Wittenberg" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD009002.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Alzheimer Disease [*drug therapy]; Cognition [drug effects]; Fatty Acids, Omega‐3 [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009002.pub3&amp;doi=10.1002/14651858.CD009002.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="jiwTpTuf";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009002\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009002\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ko","ms","ja","hr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009002.pub3",title:"Omega\\u20103 fatty acids for the treatment of dementia",firstPublishedDate:"Apr 11, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009002.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009002.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009002.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009002.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009002.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009002.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009002.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009002.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009002.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009002.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>16568 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009002.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-abs-0007"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-sec-0109"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-sec-0074"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-sec-0103"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/appendices#CD009002-sec-0114"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/table_n/CD009002StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/table_n/CD009002StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Omega‐3 fatty acids for the treatment of dementia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information#CD009002-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Marion Burckhardt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information#CD009002-cr-0003">Max Herke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information#CD009002-cr-0004">Tobias Wustmann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information#CD009002-cr-0005">Stefan Watzke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information#CD009002-cr-0006">Gero Langer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information#CD009002-cr-0007">Astrid Fink</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information/en#CD009002-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009002.pub3">https://doi.org/10.1002/14651858.CD009002.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009002-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009002-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009002-abs-0002">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009002-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009002-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009002-abs-0005">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009002-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009002-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009002-abs-0001" lang="en"> <section id="CD009002-sec-0001"> <h3 class="title" id="CD009002-sec-0001">Background</h3> <p>Omega‐3 polyunsaturated fatty acids (omega‐3 PUFAs) from fish and plant sources are commonly considered as a promising non‐medical alternative to improve brain functions and slow down the progression of dementia. This assumption is mostly based on findings of preclinical studies and epidemiological research. Resulting explanatory models aim at the role omega‐3 PUFAs play in the development and integrity of the brain's neurons, their protective antioxidative effect on cell membranes and potential neurochemical mechanisms directly related to Alzheimer‐specific pathology. Epidemiological research also found evidence of malnutrition in people with dementia. Considering this and the fact that omega‐3 PUFA cannot be synthesised by humans, omega‐3 PUFAs might be a promising treatment option for dementia. </p> </section> <section id="CD009002-sec-0002"> <h3 class="title" id="CD009002-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of omega‐3 polyunsaturated fatty acid (PUFA) supplementation for the treatment of people with dementia. </p> </section> <section id="CD009002-sec-0003"> <h3 class="title" id="CD009002-sec-0003">Search methods</h3> <p>We searched the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (ALOIS), MEDLINE, EMBASE, PsycINFO, CINAHL, ClinicalTrials.gov and the World Health Organization (WHO) portal/ICTRP on 10 December 2015. We contacted manufacturers of omega‐3 supplements and scanned reference lists of landmark papers and included articles. </p> </section> <section id="CD009002-sec-0004"> <h3 class="title" id="CD009002-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) in which omega‐3 PUFA in the form of supplements or enriched diets were administered to people with Alzheimer's disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), Parkinson's disease dementia (PDD) or frontotemporal dementia (FTD). </p> </section> <section id="CD009002-sec-0005"> <h3 class="title" id="CD009002-sec-0005">Data collection and analysis</h3> <p>The primary outcome measures of interest were changes in global and specific cognitive functions, functional performance, dementia severity and adverse effects. Two review authors independently selected studies, extracted data and assessed the quality of trials according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. We rated the quality of the evidence using the GRADE approach. We received unpublished data from the trial authors and collected adverse effects information from the published articles. We conducted meta‐analyses for available outcome measures at six months. </p> </section> <section id="CD009002-sec-0006"> <h3 class="title" id="CD009002-sec-0006">Main results</h3> <p>We included three comparable randomised, placebo‐controlled trials investigating omega‐3 PUFA supplements in 632 participants with mild to moderate AD over six, 12 and 18 months. We found no studies investigating other types of dementia. All trials were of high methodological quality. The overall quality of evidence for most of the outcomes was high. </p> <p>There was no evidence of a benefit from omega‐3 PUFAs on cognitive function when measured at six months with the Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (standardised mean difference (SMD) ‐0.02, 95% confidence interval (CI) ‐0.19 to 0.15; 566 participants; 3 studies; high quality evidence) or Mini‐Mental State Examination (mean difference (MD) 0.18, 95% CI ‐1.05 to 1.41; 202 participants; 2 studies; high quality evidence) or on activities of daily living (SMD ‐0.02, 95% CI ‐0.19 to 0.16; 544 participants; 2 studies; high quality evidence). There was also no effect at six months of treatment on severity of dementia measured with the Clinical Dementia Rating ‐ Sum of Boxes (MD ‐0.00, 95% CI ‐0.58 to 0.57; 542 participants; 2 studies; high quality evidence) or on quality of life measured with the Quality of Life Alzheimer's Disease scale (MD ‐0.10, 95% CI ‐1.28 to 1.08; 322 participants; 1 study; high quality evidence). There was no difference at six months on mental health measured with the Montgomery‐Åsberg Depression Rating Scale (MD ‐0.10, 95% CI ‐0.74 to 0.54; 178 participants: 1 study; high quality of evidence) or the Neuropsychiatric Inventory (SMD 0.10, 95% CI ‐0.07 to 0.27; 543 participants; 2 studies; high quality of evidence). One very small study showed a benefit for omega‐3 PUFAs in instrumental activities of daily living after 12 months of treatment (MD ‐3.50, 95% CI ‐4.30 to ‐2.70; 22 participants; moderate quality evidence). The included studies did not measure specific cognitive function. The studies did not report adverse events well. Two studies stated that all adverse events were mild and that they did not differ in overall frequency between omega‐3 PUFA and placebo groups. Data from one study showed no difference between groups in frequency of any adverse event (risk ratio (RR) 1.02, 95% CI 0.95 to 1.10; 402 participants; 1 study; moderate quality evidence) or any serious adverse event (RR 1.05, 95% CI 0.78 to 1.41; 402 participants; 1 study; high quality evidence) at 18 months of treatment. </p> </section> <section id="CD009002-sec-0007"> <h3 class="title" id="CD009002-sec-0007">Authors' conclusions</h3> <p>We found no convincing evidence for the efficacy of omega‐3 PUFA supplements in the treatment of mild to moderate AD. This result was consistent for all outcomes relevant for people with dementia. Adverse effects of omega‐3 PUFAs seemed to be low, but based on the evidence synthesised in this review, we cannot make a final statement on tolerability. The effects on other populations remain unclear. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009002-abs-0007" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009002-abs-0007">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009002-abs-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009002-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009002-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009002-abs-0014">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD009002-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD009002-abs-0011">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009002-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009002-abs-0015">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009002-abs-0010">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD009002-abs-0009">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009002-abs-0007" lang="en"> <h3>Omega‐3 fatty acids for the treatment of dementia</h3> <p><b>Background</b> </p> <p>Omega‐3 polyunsaturated fatty acids (omega‐3 PUFAs) are assumed to have a beneficial effect on the function of the brain. It has been suggested that they might improve or delay decline in memory and ability to carry out everyday tasks in people with dementia. In this review, we investigated randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) comparing omega‐3 PUFAs, given in the form of supplements or enriched diets, with placebo (a pretend treatment) in people with the most common types of dementia. </p> <p><b>Included trials</b> </p> <p>We included three trials that investigated 632 people with Alzheimer's disease of mild to moderate severity. We found no trials on other types of dementia. In all trials participants took either placebo or omega‐3 PUFA supplements. The quality of the trials was good. The participants were allocated to the groups randomly. The participants and most of the investigators did not know which treatment was given. </p> <p><b>Results</b> </p> <p>When we combined the results of the trials, we found that taking omega‐3 PUFA supplements for six months had no effect on cognition (learning and understanding), everyday functioning, quality of life or mental health. One very small study observed that omega‐3 PUFAs improved cognitively complex daily activities, such as shopping, when taken for a longer period of time. However, the quality of the evidence was only moderate, so this should be confirmed in further trials. Omega‐3 PUFAs also had no effect on ratings of the overall severity of the illness. The trials did not report side effects very well, but none of the studies reported significant harmful effects on health. </p> <p><b>Conclusion</b> </p> <p>Altogether, the quality of the evidence was moderate or high for most of the effects that we measured, but we found no evidence for either benefit or harm from omega‐3 PUFA supplements in people with mild to moderate Alzheimer's disease. The effects on people with other types of dementia remain unclear. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009002-sec-0109" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009002-sec-0109"></div> <h3 class="title" id="CD009002-sec-0110">Implications for practice</h3> <section id="CD009002-sec-0110"> <p>We found no convincing evidence for efficacy of omega‐3 polyunsaturated fatty acids (omega‐3 PUFA) supplements in the treatment of mild to moderate Alzheimer's disease (AD). This result was based on high quality evidence and was consistent across all of the outcomes relevant for people with AD. It is possible that omega‐3 PUFAs improve instrumental activities of daily living, such as more complex activities (i.e. shopping), when taken for a longer period of time, but this has to be confirmed in further trials. Adverse effects of omega‐3 PUFAs seem to be uncommon, but based on the evidence synthesised in this review, we cannot make a definite statement on the tolerability of omega‐3 PUFA supplements. </p> <p>The effects on other populations of people with dementia remain unclear.</p> </section> <h3 class="title" id="CD009002-sec-0111">Implications for research</h3> <section id="CD009002-sec-0111"> <p>Based on consistent results from high quality evidence, we do not believe any further studies investigating the same treatment regimen in people with mild to moderate AD would yield any other results related to cognition and basic function. However, it remains unclear if people with other types of dementia or differing levels of severity of dementia would benefit from omega‐3 PUFAs. This applies in particular for people with a docosahexaenoic acid (DHA) deficit. Therefore, future trials should provide pre‐specified subgroup analyses for people with malnutrition or low DHA levels. </p> <p>Based on current discussions (<a href="./references#CD009002-bbs2-0035" title="European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. EMA/CHMP/539931/2014 Corr. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176827.pdf (accessed 23 October 2014). ">EMA 2014</a>; <a href="./references#CD009002-bbs2-0094" title="VellasB , AndrieuS , SampaioC , ColeyN , WilcockG . Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurology2008;7:436‐50. ">Vellas 2008</a>), it may prove favourable to assess cognition with outcome measures more sensitive to change versus the regular scales (e.g. <a href="./references#CD009002-bbs2-0046" title="HarrisonJ , MinassianSL , JenkinsL , BlackRS , KollerM , GrundmanM . A neuropsychological test battery for use in Alzheimer disease clinical trials. Archives of Neurology2007;64(9):1323‐9. ">Harrison 2007</a>). It can also be hypothesised that changes in instrumental activities of daily living (i.e. doing finances) are more likely to be detected in early stages of dementia. Therefore, future trials should also consider using measures for instrumental activities of daily living. </p> <p>More emphasis should be placed on statistical issues because the proportion of missing data in trials investigating dementia can be high. Simple methods such as last observation carried forward are seemingly attractive for longitudinal designs, but often cause bias due to several shortcomings. Possibly the most obvious and severe being that it ignores the progressive course of dementia disease (<a href="./references#CD009002-bbs2-0067" title='MolnarFJ , HuttonB , FergussonD . Does analysis using "last observation carried forward" introduce bias in dementia research?. Canadian Medical Association Journal2008;179(8):751‐3. [PUBMED: 18838445] '>Molnar 2008</a>). Mixed models for repeated measures and slope‐based analyses can also overestimate the effect (<a href="./references#CD009002-bbs2-0035" title="European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. EMA/CHMP/539931/2014 Corr. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176827.pdf (accessed 23 October 2014). ">EMA 2014</a>). Both models do not account for the possibility of a less favourable course for people discontinuing the study. In a European Medicines Agency (EMA) discussion paper, several alternative choices of analyses and sensitivity analyses were suggested to accompany the primary analysis (<a href="./references#CD009002-bbs2-0035" title="European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. EMA/CHMP/539931/2014 Corr. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176827.pdf (accessed 23 October 2014). ">EMA 2014</a>). Such additional calculations can be useful to interpret the data, provided that the assumptions and methods for imputed data are described and the assumed effect and variability measures are presented. Following the suggestion of <a href="./references#CD009002-bbs2-0068" title="MolnarFJ , Man‐Son‐HingM , FergussonD . Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. Journal of the American Geriatrics Society2009;57:536‐46. ">Molnar 2009</a>, it might further support interpretability and decision making, if minimal clinically important differences of outcome measures are determined as a complementary part in randomised controlled trials investigating omega‐3 PUFAs for dementia. It can be reasonably assumed that for many people affected by cognitive decline, the trade‐off between effectiveness, adverse effects and costs of nutritional supplements differs from that of drugs prescribed for dementia. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009002-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009002-sec-0043"></div> <div class="table" id="CD009002-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Omega‐3 PUFA supplements compared to placebo for people with mild to moderate Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Omega‐3 PUFA supplements compared to placebo for people with mild to moderate Alzheimer's disease </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mild to moderate Alzheimer's disease<br/> <b>Setting:</b> any setting<br/> <b>Intervention:</b> omega‐3 PUFA supplements<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo for mild to moderate Alzheimer's disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with omega‐3 PUFAs for mild to moderate Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any adverse event (combined: diarrhoea, urinary tract infection, falls, dizziness, agitations)<br/> Assessed with: unclear<br/> Follow‐up: mean 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.02<br/> (0.95 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>402<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>878 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>896 per 1000<br/> (834 to 966) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>878 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>896 per 1000<br/> (834 to 966) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events<br/> "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.78 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>402<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>305 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000<br/> (238 to 430) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL</p> <p>Assessed with: QoL‐AD scale rated by participant<br/> Scale from 13 to 52 (higher = better)<br/> Follow‐up: mean 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean QoL was 40.02 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in QoL in the intervention group was 0.39 scale points fewer (1.79 fewer to 1.01 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL<br/> Assessed with: QoL‐AD scale rated by participant<br/> Scale from 13 to 52 (higher = better)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean QoL was 39.86 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in QoL in the intervention group was 0.1 scale points fewer (1.28 fewer to 1.08 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>332<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental health (depression)<br/> Assessed with: MADRS<br/> Scale from 0 to 30 (lower = better)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression (MADRS) score was 1.6 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in depression (MADRS) score in the intervention group was 0.1 scale points fewer (0.74 fewer to 0.54 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental health</p> <p>Assessed with: NPI</p> <p>Follow‐up: mean 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean difference in mental health (NPI) score in the intervention group was 0.1 standard deviations more (0.07 fewer to 0.27 more) <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cognitive function<br/> Assessed with: ADAS‐Cog (different versions)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean difference in global cognitive function (ADAS‐Cog) in the intervention group was 0.02 standard deviations fewer (0.19 fewer to 0.15 more) 4 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>566<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cognitive function<br/> assessed with: MMSE scale<br/> Scale from 0 to 30 (higher = better)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global cognitive function ranged from 20.4 to 22.4 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in global cognitive function (MMSE) in the intervention group was 0.18 scale points more (1.05 fewer to 1.41 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IADL<br/> Assessed with: OARS‐IADL<br/> Scale from 0 to 14 (lower = better)<br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in score for IADL was 4.2 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in the change in score for IADL in the intervention group was 3.5 scale points lower (4.3 lower to 2.7 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<br/> Assessed with: DAD and ADCS‐ADL<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean difference in ADL in the intervention group was 0.02 standard deviations fewer (0.19 fewer to 0.16 more)<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>544<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall dementia severity (cognition and function combined)<br/> Assessed with: CDR‐SOB<br/> Scale from 0 to 18 (lower = better)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall dementia severity (CDR‐SOB score) ranged from 6.5 to 6.75 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in overall dementia severity (CDR‐SOB score) in the intervention group was 0 scale points (0.58 fewer to 0.57 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADAS‐Cog:</b> Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; <b>ADCS‐ADL:</b> Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; <b>ADL:</b> activities of daily living; <b>CDR‐SOB:</b> Clinical Dementia Rating ‐ Sum of Boxes; <b>CI:</b> confidence interval; <b>DAD:</b> Disability Assessment for Dementia; <b>IADL:</b> instrumental activities of daily living; <b>NPI:</b> Neuropsychiatric Inventory; <b>MADRS:</b> Montgomery‐Åsberg Depression Rating Scale; <b>MMSE:</b> Mini‐Mental State Examination; <b>OARS‐IADL:</b> Older Americans Resources and Services ‐ Instrumental Activities of Daily Living; <b>OR:</b> odds ratio; <b>PUFA:</b> polyunsaturated fatty acid; <b>QoL:</b> quality of life; <b>QoL‐AD:</b> Quality of Life Alzheimer's Disease; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias: combined outcome (i.e. diarrhoea, falls, agitation) that includes outcomes of unclear measurement methods (i.e. dizziness). </p> <p><sup>2</sup> Downgraded one level due to serious risk of bias: follow‐up differed between groups: 63.0% (omega‐3 PUFAs) and 72.6% (placebo). </p> <p><sup>3</sup> Downgraded one level due to serious imprecision: wide CI; only 22 participants overall. </p> <p><sup>4</sup> SMD presented in place of absolute values in the intervention and comparison groups as studies used the different scale versions. </p> <p><sup>5</sup> SMD presented in place of absolute values in the interventions and comparison groups as studies used different scales to measure the same construct. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009002-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009002-sec-0044"></div> <section id="CD009002-sec-0045"> <h3 class="title" id="CD009002-sec-0045">Description of the condition</h3> <p>The number of people living with dementia is increasing due to the ageing world population (<a href="./references#CD009002-bbs2-0090" title="United Nations Department of Economic and Social Affairs Population Division. World Population Ageing 2013. www.un.org/en/development/desa/population/publications/ (accessed 10 June 2014). ">United Nations 2013)</a>, with higher age being the major risk factor for the disease. In 2012, 35 million people were estimated to be affected worldwide. This number will double by 2030 resulting in high costs and considerable burden to individuals and societies (<a href="./references#CD009002-bbs2-0098" title="World Health Organization, Alzheimer's Disease International. Dementia. A public health priority, 2012. Available from www.who.int/mental_health/publications/dementia_report_2012/en/ (accessed 31 March 2016). [ISBN 978 92 4 156445 8] ">WHO 2012</a>). </p> <p>The term 'dementia' refers to a group of diseases that share a syndrome of typically chronic and progressive nature. The dementia syndrome involves disturbances of multiple higher cortical functions, such as memory, thinking, orientation, perception and behaviour, which are severe enough to affect the ability to perform everyday activities. Cognitive decline is often accompanied by deterioration in emotional control, social behaviour or motivation. The most common forms of dementia are Alzheimer's disease (AD) (60% to 70% of cases), vascular dementia (VaD), dementia with Lewy bodies (DLB), dementia in Parkinson's disease (PDD) and frontotemporal dementia (FTD). </p> <p>The early stages of the disease are typically characterised by forgetfulness, communication problems and difficulties in carrying out complex activities. In the middle stage, the symptoms become more obvious and people gradually lose the ability to care for themselves without considerable support. In the late or severe stages of dementia, people are dependent on others for all care, and psychiatric and behavioural symptoms are increasingly common (<a href="./references#CD009002-bbs2-0098" title="World Health Organization, Alzheimer's Disease International. Dementia. A public health priority, 2012. Available from www.who.int/mental_health/publications/dementia_report_2012/en/ (accessed 31 March 2016). [ISBN 978 92 4 156445 8] ">WHO 2012</a>). </p> <p>Medical treatments for dementia are limited. Licensed medications are available only for dementia due to AD and PDD and these have only modest benefits for symptoms. Many people are interested in non‐medical options to slow down cognitive decline. These include lifestyle modifications and the reduction of modifiable risk factors (<a href="./references#CD009002-bbs2-0098" title="World Health Organization, Alzheimer's Disease International. Dementia. A public health priority, 2012. Available from www.who.int/mental_health/publications/dementia_report_2012/en/ (accessed 31 March 2016). [ISBN 978 92 4 156445 8] ">WHO 2012</a>). Data from <a href="./references#CD009002-bbs2-0057" title="LarsonEB , YaffeK , LangaKM . New insights into the dementia epidemic. New England Journal of Medicine2013;369:2275‐7. ">Larson 2013</a> indicate that the incidence of dementia may be falling, which supports the theory that individual risk might be modifiable. Currently, regular physical exercise, sleep hygiene, mental training and a healthy diet are often recommended to maintain a good physical and cognitive condition (<a href="./references#CD009002-bbs2-0018" title="BarnardND , BushAI , CeccarelliA , CooperJ , deJagerCA , EricksonKI , et al. Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. Neurobiology of Aging2014;35:S74‐8. ">Barnard 2014</a>). Furthermore, there is a growing body of research indicating that malnutrition, which is strongly associated with cognitive decline, is a common problem of people with dementia (<a href="./references#CD009002-bbs2-0077" title="ReutherS , vanNieN , MeijersJ , HalfensR , BartholomeyczikS . Malnutrition and dementia in the elderly in German nursing homes. Results of a prevalence survey from the years 2008 and 2009 [Mangelernährung und Demenz bei Bewohnern in Einrichtungen der stationären Altenpflege in Deutschland]. Zeitschrift für Gerontologie und Geriatrie2013;46:260‐7. ">Reuther 2013</a>; <a href="./references#CD009002-bbs2-0081" title="RoqueM , SalvaA , VellasB . Malnutrition in community‐dwelling adults with dementia (NutriAlz Trial). Journal of Nutrition, Health and Aging2013;17:295‐9. ">Roque 2013</a>; <a href="./references#CD009002-bbs2-0093" title="VellasB , LauqueS , Gillette‐GuyonnetS , AndrieuS , CortesF , NourhashemiF , et al. Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment. Journal of Nutrition, Health and Aging2005;9:75‐80. ">Vellas 2005</a>). Dietary recommendations for people with AD aim at a healthy balanced diet containing vegetables, legumes, fruits and whole grains (<a href="./references#CD009002-bbs2-0018" title="BarnardND , BushAI , CeccarelliA , CooperJ , deJagerCA , EricksonKI , et al. Dietary and lifestyle guidelines for the prevention of Alzheimer's disease. Neurobiology of Aging2014;35:S74‐8. ">Barnard 2014</a>). It is hoped that nutritional interventions might be a reasonable approach to delay the progression of the disease. </p> </section> <section id="CD009002-sec-0046"> <h3 class="title" id="CD009002-sec-0046">Description of the intervention</h3> <p>Omega‐3 long‐chain polyunsaturated fatty acids (omega‐3 PUFAs) play a major role in human organs and their function. They are involved in inflammatory and immunological processes and hormonal regulation. Furthermore, they are a component of neuronal membranes and involved in the development and function of the brain (<a href="./references#CD009002-bbs2-0088" title="SuHM . Mechanisms of n‐3 fatty acid‐mediated development and maintenance of learning memory performance. Journal of Nutritional Biochemistry2010;21:364‐73. ">Su 2010</a>). </p> <p>The human body cannot synthesise omega‐3 PUFAs. Therefore, they are classified as essential fatty acids<i>.</i> The most common omega‐3 PUFAs are eicosapentaenoic acid (EPA, 20:5n‐3), docosahexaenoic acid (DHA, 22:6n‐3) and alpha‐linolenic acid (ALA, 18:3n‐3). Chemically, fatty acids chains consist of carbon atoms with a carboxylic end ('alpha') and methyl end ('omega'). The first number of the chemical name refers to the number of carbons in the carbon chain. It is followed by the number of double bonds and their position counting from the omega end of the chain (i.e. 'n‐3' refers to the C=C double bond at position three). </p> <p>Natural sources of EPA and DHA are algae, oily fish (e.g. salmon, mackerel, herring or sardines) and fish oils. In plants, the most common ALA is found in vegetable oils (e.g. canola, flax seed oil, soybean oil) and nuts (e.g. walnuts). Humans cannot synthesise ALA, but it can be partially metabolised into EPA and DHA (<a href="./references#CD009002-bbs2-0038" title="Food , Agriculture Organization of the United Nations(FAO) . Fats and fatty acids in human nutrition. Report of an expert consultation. 10‐14 November 2008, Geneva. FAO Food and Nutrition Paper 91. Rome, 2010:188. [ISBN 978‐92‐5‐106733‐8] ">FAO 2010</a>). Nutritional supplements containing oils rich in omega‐3 PUFAs are also available. There is broad scientific consensus about the importance of food sources rich in omega‐3 PUFAs to maintain healthy body function. However, the evidence on the supportive role of additional supplements is still insufficient (<a href="./references#CD009002-bbs2-0022" title="CampbellA , PriceJ , HiattWR . Omega‐3 fatty acids for intermittent claudication. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003833.pub4] ">Campbell 2013</a>; <a href="./references#CD009002-bbs2-0032" title="EFSA Panel on DieteticProducts , Nutrition , Allergies(NDA) . Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal2010;8(3):1461. [DOI: 10.2903/j.efsa.2010.1461] ">EFSA 2010</a>; <a href="./references#CD009002-bbs2-0051" title="HooperL , ThompsonRL , HarrisonRA , SummerbellCD , MooreH , WorthingtonHV , et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD003177.pub2] ">Hooper 2004</a>). This applies in particular to the prevention of dementia (<a href="./references#CD009002-bbs2-0089" title="SydenhamE , DangourAD , LimW‐S . Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005379.pub3] ">Sydenham 2012</a>). </p> <p>The human body has a limited storage capacity of PUFAs in adipose tissue, which implies their regular consumption (<a href="./references#CD009002-bbs2-0016" title="ArterburnLM , HallEB , OkenH . Distribution, interconversion, and dose response of n‐3 fatty acids in humans. American Journal of Clinical Nutrition2006;83:1467S‐76S. ">Arterburn 2006</a>). Most guidelines recommend a daily intake of 250 to 1000 mg of EPA plus DHA to meet the requirements of a healthy diet in adults. An adequate intake of ALA is generally expressed as 'percentage of total dietary energy (E%)' (<a href="./references#CD009002-bbs2-0032" title="EFSA Panel on DieteticProducts , Nutrition , Allergies(NDA) . Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal2010;8(3):1461. [DOI: 10.2903/j.efsa.2010.1461] ">EFSA 2010</a>) and usually defined to be 0.5E% to 1.0E% (<a href="./references#CD009002-bbs2-0015" title="ArancetaJ , Perez‐RodrigoC . Recommended dietary reference intakes, nutritional goals and dietary guidelines for fat and fatty acids: a systematic review. British Journal of Nutrition2012;107 Suppl 2:S8‐22. ">Aranceta 2012</a>; <a href="./references#CD009002-bbs2-0032" title="EFSA Panel on DieteticProducts , Nutrition , Allergies(NDA) . Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal2010;8(3):1461. [DOI: 10.2903/j.efsa.2010.1461] ">EFSA 2010</a>). However dietary reference values and guideline recommendations vary across the world (<a href="./references#CD009002-bbs2-0015" title="ArancetaJ , Perez‐RodrigoC . Recommended dietary reference intakes, nutritional goals and dietary guidelines for fat and fatty acids: a systematic review. British Journal of Nutrition2012;107 Suppl 2:S8‐22. ">Aranceta 2012</a>; <a href="./references#CD009002-bbs2-0033" title="European Food Safety Authority (EFSA). Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). EFSA Journal2012;10(7):2815. [DOI: 10.2903/j.efsa.2012.2815] ">EFSA 2012</a>). The optimal amounts for the prevention and treatment of chronic diseases are not well established (<a href="./references#CD009002-bbs2-0064" title="MichaR , KhatibzadehS , ShiP , FahimiS , LimS , AndrewsKG , et al. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country‐specific nutrition surveys. BMJ2014;348:g2272. ">Micha 2014</a>). Experts state that the recommended amounts of omega‐3 PUFAs can be consumed as part of a balanced diet with a regular intake of fish (<a href="./references#CD009002-bbs2-0032" title="EFSA Panel on DieteticProducts , Nutrition , Allergies(NDA) . Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal2010;8(3):1461. [DOI: 10.2903/j.efsa.2010.1461] ">EFSA 2010</a>). For example, an intake of 500 mg of EPA plus DHA can be achieved by consuming two portions (90 g) of oily fish per week (<a href="./references#CD009002-bbs2-0038" title="Food , Agriculture Organization of the United Nations(FAO) . Fats and fatty acids in human nutrition. Report of an expert consultation. 10‐14 November 2008, Geneva. FAO Food and Nutrition Paper 91. Rome, 2010:188. [ISBN 978‐92‐5‐106733‐8] ">FAO 2010</a>). Nevertheless, omega‐3 PUFA supplements are among the most consumed of dietary supplements intended to improve or maintain overall health (<a href="./references#CD009002-bbs2-0017" title="BaileyRL , GahcheJJ , MillerPE , ThomasPR , DwyerJT . Why US adults use dietary supplements. JAMA International Medicine2013;173:355‐61. ">Bailey 2013</a>; <a href="./references#CD009002-bbs2-0029" title="DickinsonA , BlatmanJ , El‐DashN , FrancoJC . Consumer usage and reasons for using dietary supplements: report of a series of surveys. Journal of the American College of Nutrition2014;33:176‐82. ">Dickinson 2014</a>). Even though current data show an overall increase of the consumption of polyunsaturated fats, people in most countries consume less than the recommended amount (<a href="./references#CD009002-bbs2-0033" title="European Food Safety Authority (EFSA). Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). EFSA Journal2012;10(7):2815. [DOI: 10.2903/j.efsa.2012.2815] ">EFSA 2012</a>; <a href="./references#CD009002-bbs2-0064" title="MichaR , KhatibzadehS , ShiP , FahimiS , LimS , AndrewsKG , et al. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country‐specific nutrition surveys. BMJ2014;348:g2272. ">Micha 2014</a>). Supplements with combined doses of DHA and EPA up to 5 g/day, EPA alone up to 1.8 g/day or DHA up to 1 g/day for adults do not raise safety concerns of the European Food Safety Authority (<a href="./references#CD009002-bbs2-0033" title="European Food Safety Authority (EFSA). Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). EFSA Journal2012;10(7):2815. [DOI: 10.2903/j.efsa.2012.2815] ">EFSA 2012</a>). </p> </section> <section id="CD009002-sec-0047"> <h3 class="title" id="CD009002-sec-0047">How the intervention might work</h3> <p>Omega‐3 PUFAs are involved in the structure and function of cell membrane phospholipid fractions in the brain (<a href="./references#CD009002-bbs2-0023" title="CansevM , WurtmanRJ , SakamotoT , UlusIH . Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. Alzheimer's &amp; Dementia2008;4:S153‐68. ">Cansev 2008</a>), and are assumed to play an important role in cognitive processes. Several hypotheses have been presented to explain how the dietary intake of omega‐3 PUFAs might influence the cognitive performance of people with dementia. </p> <p>First, maintaining adequate levels of omega‐3 PUFAs may support the development and integrity of the brain's neurons and enhance synaptic plasticity (<a href="./references#CD009002-bbs2-0023" title="CansevM , WurtmanRJ , SakamotoT , UlusIH . Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses. Alzheimer's &amp; Dementia2008;4:S153‐68. ">Cansev 2008</a>; <a href="./references#CD009002-bbs2-0088" title="SuHM . Mechanisms of n‐3 fatty acid‐mediated development and maintenance of learning memory performance. Journal of Nutritional Biochemistry2010;21:364‐73. ">Su 2010</a>). Research shows a risk of malnutrition in people with dementia (<a href="./references#CD009002-bbs2-0077" title="ReutherS , vanNieN , MeijersJ , HalfensR , BartholomeyczikS . Malnutrition and dementia in the elderly in German nursing homes. Results of a prevalence survey from the years 2008 and 2009 [Mangelernährung und Demenz bei Bewohnern in Einrichtungen der stationären Altenpflege in Deutschland]. Zeitschrift für Gerontologie und Geriatrie2013;46:260‐7. ">Reuther 2013</a>; <a href="./references#CD009002-bbs2-0081" title="RoqueM , SalvaA , VellasB . Malnutrition in community‐dwelling adults with dementia (NutriAlz Trial). Journal of Nutrition, Health and Aging2013;17:295‐9. ">Roque 2013</a>; <a href="./references#CD009002-bbs2-0093" title="VellasB , LauqueS , Gillette‐GuyonnetS , AndrieuS , CortesF , NourhashemiF , et al. Impact of nutritional status on the evolution of Alzheimer's disease and on response to acetylcholinesterase inhibitor treatment. Journal of Nutrition, Health and Aging2005;9:75‐80. ">Vellas 2005</a>), which indicates that vulnerable people in particular can benefit from additional administration of omega‐3 PUFAs. Findings of decreased fatty acids in plasma within this population might support this idea (<a href="./references#CD009002-bbs2-0060" title="LinPY , ChiuCC , HuangSY , SuKP . A meta‐analytic review of polyunsaturated fatty acid compositions in dementia. Journal of Clinical Psychiatry2012;73(9):1245‐54. ">Lin 2012</a>; <a href="./references#CD009002-bbs2-0062" title="Lopes da SilvaS , VellasB , ElemansS , LuchsingerJ , KamphuisP , YaffeK , et al. Plasma nutrient status of patients with Alzheimer's disease: systematic review and meta‐analysis. Alzheimer's &amp; Dementia2013;10(4):485‐502. ">Lopes da Silva 2013</a>). </p> <p>Second, omega‐3 PUFAs have anti‐oxidative and anti‐inflammatory effects (<a href="./references#CD009002-bbs2-0066" title="MolfinoA , GioiaG , FanelliFR , MuscaritoliM . The role for dietary omega‐3 fatty acids supplementation in older adults. Nutrients2014;6:4058‐72. ">Molfino 2014</a>; <a href="./references#CD009002-bbs2-0092" title="VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. ">Vedin 2012</a>). Especially in the ageing brain, this characteristic may contribute to the protection of neurons and prevent cellular death. </p> <p>Third, Morris and Tangne have argued in their review that the fatty acid composition of the diet is an important determinant of blood cholesterol, which in turn seems to play a role in the pathology of AD (<a href="./references#CD009002-bbs2-0071" title="MorrisMC , TangneyCC . Dietary fat composition and dementia risk. Neurobiology of Aging2014;35 Suppl 2:S59‐64. ">Morris 2014</a>). For example, apolipoprotein‐E (ApoE) is involved in the transport of cholesterol and the ApoE‐ϵ4 allele is an important risk factor for AD (<a href="./references#CD009002-bbs2-0071" title="MorrisMC , TangneyCC . Dietary fat composition and dementia risk. Neurobiology of Aging2014;35 Suppl 2:S59‐64. ">Morris 2014</a>). Furthermore, there is growing evidence that serum cholesterol is strongly associated with the deposition of β‐amyloid in the human brain (<a href="./references#CD009002-bbs2-0076" title="ReedB , VilleneuveS , MackW , DeCarliC , ChuiHC , JagustW . Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurology2014;71:195‐200. ">Reed 2014</a>). </p> <p>Finally, it has also been suggested that omega‐3 PUFAs may be directly related to the decrease of AD‐specific pathology (e.g. Aβ levels) (<a href="./references#CD009002-bbs2-0024" title="ColeGM , MaQL , FrautschySA . Omega‐3 fatty acids and dementia. Prostaglandins, Leukotrienes, and Essential Fatty Acids2009;81:213‐21. ">Cole 2009</a>; <a href="./references#CD009002-bbs2-0088" title="SuHM . Mechanisms of n‐3 fatty acid‐mediated development and maintenance of learning memory performance. Journal of Nutritional Biochemistry2010;21:364‐73. ">Su 2010</a>). This hypothesis is supported to some extent by preclinical studies, and a wide range of models describing potential neurochemical mechanisms have been outlined (<a href="./references#CD009002-bbs2-0072" title="MurphyT , DiasGP , ThuretS . Effects of diet on brain plasticity in animal and human studies: mind the gap. Neural Plasticity2014;2014:563160. ">Murphy 2014</a>; <a href="./references#CD009002-bbs2-0088" title="SuHM . Mechanisms of n‐3 fatty acid‐mediated development and maintenance of learning memory performance. Journal of Nutritional Biochemistry2010;21:364‐73. ">Su 2010</a>). </p> </section> <section id="CD009002-sec-0048"> <h3 class="title" id="CD009002-sec-0048">Why it is important to do this review</h3> <p>Omega‐3 PUFAs have become increasingly important in several dietary recommendations. It is widely theorised that they slow cognitive decline in people with dementia. Considering the enormous impact of dementia on quality of life (QoL) and the limited treatment possibilities, a safe and effective dietary intervention would be of great interest to people with dementia. With this review, we aimed to assist them in their decision regarding dietary supplementation with omega‐3 PUFAs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009002-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009002-sec-0049"></div> <p>To assess the efficacy and safety of omega‐3 polyunsaturated fatty acid (PUFA) supplementation for the treatment of people with dementia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009002-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009002-sec-0050"></div> <section id="CD009002-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009002-sec-0052"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs). Since dementia is a progressive disease, we included only the data of the first period of cross‐over randomised trials. </p> </section> <section id="CD009002-sec-0053"> <h4 class="title">Types of participants</h4> <p>We included people diagnosed with AD, VaD, DLB, PDD and FTD. The diagnosis of dementia should have been made in accordance with accepted guidelines, such as the Diagnostic and Statistical Manual of Mental Disorders (<a href="./references#CD009002-bbs2-0012" title="American Psychiatric Association. Diagnostic and StatisticalManual of Mental Disorders [American Psychiatric Association, 1987.]. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington D.C.: American Psychiatric Association, 1987. ">APA 1987</a>; <a href="./references#CD009002-bbs2-0013" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington D.C.: American Psychiatric Association, 1994. ">APA 1994</a>; <a href="./references#CD009002-bbs2-0014" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington, VA: American Psychiatric Publishing, 2013. ">APA 2013</a>), the International Classification of Diseases (ICD; <a href="./references#CD009002-bbs2-0096" title="World Health Organization. The ICD‐10 classification of mental and behavioural disorders: clinical description and diagnostic guidelines. Geneva: World Health Organization, Division of Mental Health, 1992. ">WHO 1992</a>; <a href="./references#CD009002-bbs2-0097" title="World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th revision. Vol. 2, Geneva: World Health Organization, 2010. [ISBN 978 92 4 154834 2] ">WHO 2010</a>), the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS)‐Alzheimer's Disease and Related Disorders Association (ADRDA) Alzheimer's Criteria (<a href="./references#CD009002-bbs2-0063" title="McKhannGM , KnopmanDS , ChertkowH , HymanBT , JackCRJ , KawasCH , et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's &amp; Dementia2011;7:263‐9. ">McKhann 2011</a>) or the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et l'Enseignement en Neurosciences (NINDS‐AIREN) Criteria for the Diagnosis of Vascular Dementia (<a href="./references#CD009002-bbs2-0080" title="RománGC , TatemichiTK , ErkinjunttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS‐AIREN International Workshop. Neurology1993;43(2):250‐60. ">Román 1993</a>). </p> <p>AD and VaD are the most common types of dementia (<a href="./references#CD009002-bbs2-0098" title="World Health Organization, Alzheimer's Disease International. Dementia. A public health priority, 2012. Available from www.who.int/mental_health/publications/dementia_report_2012/en/ (accessed 31 March 2016). [ISBN 978 92 4 156445 8] ">WHO 2012</a>). Therefore, we intended to evaluate studies in which the participants were diagnosed with dementia, even if the types of dementia were not specified. However, we found only studies investigating omega‐3 PUFAs in people diagnosed with AD. </p> <p>We considered any stages and severity of dementia. Participants may have been recruited from any setting. </p> </section> <section id="CD009002-sec-0054"> <h4 class="title">Types of interventions</h4> <p>We evaluated the following interventions:</p> <p> <ul id="CD009002-list-0001"> <li> <p>Omega‐3 PUFA capsules as a dietary supplement versus placebo. We considered a supplement as appropriate for inclusion if its main active ingredient was omega‐3 PUFA; </p> </li> <li> <p>Diets enriched with omega‐3 PUFAs in specific portions versus usual diet.</p> </li> </ul> </p> <p>We considered any dosage of administration if the study participants received it on a regular basis (at least weekly) for at least 26 weeks. </p> <p>We excluded studies that only investigated dietary advice. We also excluded trials that did not precisely specify the intake of omega‐3 PUFA. </p> </section> <section id="CD009002-sec-0055"> <h4 class="title">Types of outcome measures</h4> <section id="CD009002-sec-0056"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009002-list-0002"> <li> <p>Changes in global and specific cognitive function measured by validated tools such as: </p> <ul id="CD009002-list-0003"> <li> <p>Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog) (<a href="./references#CD009002-bbs2-0082" title="RosenWG , MohsRC , DavisKL . A new rating scale for Alzheimer's disease. American Journal of Psychiatry1984;141:1356‐64. ">Rosen 1984</a>); </p> </li> <li> <p>Mini‐Mental State Examination (MMSE) (<a href="./references#CD009002-bbs2-0041" title='FolsteinMF , FolsteinSE , McHughPR . "Mini‐mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12:189‐98. '>Folstein 1975</a>); </p> </li> <li> <p>Rey Auditory Verbal Learning Test (RAVLT) (<a href="./references#CD009002-bbs2-0083" title="SchmidtM . Rey Auditory Verbal Learning Test™ (RAVLT™). A handbook, 1996. www.wpspublish.com/app/ (accessed 31 March 2016). ">Schmidt 1996</a>); </p> </li> <li> <p>Wechsler Memory Scale (<a href="./references#CD009002-bbs2-0095" title="WechslerD . Wechsler Memory Scale. 4th Edition. San Antonio, TX: Pearson, 2010. ">Wechsler 2010</a>). </p> </li> </ul> </li> <li> <p>Changes in functional outcomes (e.g. activities of daily living (ADL)) measured by validated tools such as: </p> <ul id="CD009002-list-0004"> <li> <p>Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living (ADCS‐ADL) (<a href="./references#CD009002-bbs2-0042" title="GalaskoD , BennettD , SanoM , ErnestoC , ThomasR , GrundmanM , et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease &amp; Associated Disorders1997;11(Suppl 2):33‐9. ">Galasko 1997</a>); </p> </li> <li> <p>Gottries‐Brane‐Steen‐Skala, ADL subscale (GBS‐ADL) (<a href="./references#CD009002-bbs2-0019" title="BråneG , GottfriesCG , WinbladB . The Gottfries‐Bråne‐Steen scale: validity, reliability and application in anti‐dementia drug trials. Dementia and Geriatric Cognitive Disorders2001;12:1‐14. ">Bråne 2001</a>). </p> </li> </ul> </li> </ul> <ul id="CD009002-list-0005"> <li> <p>Overall dementia severity measured by validated tools such as:</p> <ul id="CD009002-list-0006"> <li> <p>Clinical Dementia Rating ‐ Sum of Boxes (CDR‐SOB) (<a href="./references#CD009002-bbs2-0074" title="O'BryantSE , WaringSC , CullumCM , HallJ , LacritzL , MassmanPJ , et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's Research Consortium study. Archives of Neurology2008;65(8):1091‐5. ">O'Bryant 2008</a>), </p> </li> <li> <p>Alzheimer's Disease Cooperative Study ‐ Clinical Global Impression of Change (CIBIC‐Plus) (<a href="./references#CD009002-bbs2-0084" title="SchneiderLS , OlinJT , DoodyRS , ClarkCM , MorrisJC , ReisbergB , et al. Validity and reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders1997;11 Suppl 2:S22‐32. ">Schneider 1997</a>). </p> </li> </ul> </li> <li> <p>Adverse effects of the intervention such as:</p> <ul id="CD009002-list-0007"> <li> <p>gastrointestinal effects;</p> </li> <li> <p>dermatological effects;</p> </li> <li> <p>taste disturbance;</p> </li> <li> <p>infection.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD009002-sec-0057"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009002-list-0008"> <li> <p>Effect of omega‐3 PUFAs on QoL.</p> </li> <li> <p>Compliance with intervention.</p> </li> <li> <p>Symptoms associated with dementia (e.g. changes in mood, alterations in circadian rhythm). </p> </li> <li> <p>Entry to institutional care.</p> </li> <li> <p>Hospital admissions.</p> </li> <li> <p>Mortality.</p> </li> </ul> </p> <p>We did not consider biomarker outcomes.</p> </section> </section> </section> <section id="CD009002-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009002-sec-0059"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>) ‐ the Cochrane Dementia and Cognitive Improvement Group's (CDCIG) specialised register on 10 December 2015. </p> <p>The Trials Search Co‐ordinator for the CDCIG maintains ALOIS, which contains studies that fall within the areas of dementia prevention, dementia treatment and management, and cognitive enhancement in healthy elderly populations. The studies are identified through: </p> <p> <ul id="CD009002-list-0009"> <li> <p>monthly searches of several major healthcare databases: MEDLINE, EMBASE, CINAHL, PsycINFO and Lilacs; </p> </li> <li> <p>monthly searches of several trial registers: ISRCTN; UMIN (Japan's Trial Register); the World Health Organization (WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, and others); </p> </li> <li> <p>quarterly search of the Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>six‐monthly searches of several grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses. </p> </li> </ul> </p> <p>To view a list of all sources searched for ALOIS see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS website (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>). </p> <p>The 'methods used in reviews' section within the editorial information about the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">CDCIG</a> shows details of the search strategies run in healthcare bibliographic databases that we use for the retrieval of reports of dementia, cognitive improvement and cognitive enhancement trials. </p> <p>We ran additional searches in MEDLINE, EMBASE, PsycINFO, CINAHL, ClinicalTrials.gov and the WHO portal/ICTRP to ensure that the search was as comprehensive and as up‐to‐date as possible. <a href="./appendices#CD009002-sec-0115">Appendix 1</a> shows the search strategy. </p> </section> <section id="CD009002-sec-0060"> <h4 class="title">Searching other resources</h4> <p>We contacted the following manufacturers of omega‐3 PUFA products and organisations for overlooked, unpublished and ongoing trials: </p> <p> <ul id="CD009002-list-0010"> <li> <p>Global Organization for EPA and DHA Omega‐3s, USA;</p> </li> <li> <p>Arjuna Natural Extracts Limited, India;</p> </li> <li> <p>FMC Health and Nutrition Epax International, Norway;</p> </li> <li> <p>Nordic Naturals, USA;</p> </li> <li> <p>DSM Nutritional Products, Netherlands;</p> </li> <li> <p>WHC Health Consulting, Belgium;</p> </li> <li> <p>Carlson Laboratories, USA;</p> </li> <li> <p>OmegaVia, USA;</p> </li> <li> <p>Ocean Blue Professional, USA;</p> </li> <li> <p>Prevention Pharmaceuticals, USA;</p> </li> <li> <p>NeuroBioPharm Inc, USA.</p> </li> </ul> </p> <p>We reviewed reference lists of included studies, trial registries and conference abstracts, and contacted authors of landmark papers for overlooked, unpublished and ongoing trials. </p> </section> </section> <section id="CD009002-sec-0061"> <h3 class="title" id="CD009002-sec-0061">Data collection and analysis</h3> <section id="CD009002-sec-0062"> <h4 class="title">Selection of studies</h4> <p>We managed all references retrieved by the searches using EndNote (X5) (<a href="./references#CD009002-bbs2-0036" title="Thomson Reuters. EndNote X5. Thomson Reuters, 2011. ">EndNote 2011</a>). The Trials Search Co‐ordinator of the CDCIG removed duplications of the same references. Afterwards, two review authors (MB and MH or MB and AF) independently examined titles and abstracts to identify eligible studies. If it was not clear whether a study was relevant, we made the decision based on the full text. Two review authors (MB and MH) evaluated full texts of relevant articles independently according to the eligibility criteria. They were not blinded to study data. We resolved disagreements by involving a third review author. We listed final decisions for the exclusion of articles that we retrieved in full text in the <a href="./references#CD009002-sec-0124" title="">Characteristics of excluded studies</a> table. </p> <p>We planned to translate full texts that were not in English or German, and if necessary employ translation services. However, as all eligible studies were already presented in English this was not necessary. We linked multiple reports and conference abstracts of the same study together. </p> </section> <section id="CD009002-sec-0063"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MB and MH) independently read and extracted the data presented in the respective article. In case of discrepancies, we involved a third review author until we reached consensus. </p> <p>We used an electronic data extraction form, including source, eligibility, methods, participants, interventions, comparators, outcomes, results and miscellaneous notes according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009002-bbs2-0049" title="HigginsJPT , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). In addition, we assessed details of funding source, declarations of interest of the primary investigators and methods used to control possible conflicts of interests. Two review authors pre‐tested the form using the first two studies and adapted afterwards. </p> <p>For continuous data, we extracted the mean value of the outcome measurement in each group (or, if this was not available, the mean change from baseline), the standard deviation (SD) and the number of participants used to measure the outcome for each group. </p> <p>For dichotomous outcomes, we extracted the number of participants in each outcome group. If the data provided were insufficient, we attempted to obtain the omitted information from the authors of the report (see the section <a href="#CD009002-sec-0067">Dealing with missing data</a>). </p> <p>One review author (MB) entered the data into Review Manager 5 (<a href="./references#CD009002-bbs2-0079" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). A second review author (MH) checked the data for accuracy. We also extracted data from ongoing studies including study name, methods, participants, interventions, outcomes, starting date, contact information and notes. </p> </section> <section id="CD009002-sec-0064"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias for each study, using the Cochrane tool for assessing risk of bias (<a href="./references#CD009002-bbs2-0050" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). We resolved any disagreements by discussion. </p> <p>We described the risk of bias of all included studies in the <a href="./references#CD009002-sec-0123" title="">Characteristics of included studies</a> table and narrative. In addition, we provided an overall judgement of included studies by a 'Risk of bias' summary (see <a href="#CD009002-fig-0001">Figure 1</a>). To prevent undue industry influence during the clinical trial process, we explicitly considered the appropriateness of all methods used. Therefore, we assessed additional criteria, which are presented in detail in <a href="#CD009002-tbl-0002">Table 1</a>. An overall rating on how these findings might have influenced the presented study results were considered as 'other bias' in the 'Risk of bias' tables. </p> <div class="figure" id="CD009002-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009002-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="table" id="CD009002-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Methods used to control bias resulting from conflict of interest</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beforehand published primary outcomes presented?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planning phase and funding: role of industry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conducting phase: role of industry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysing process: role of industry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting process: role of industry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The OmegAD study was funded in part by Pronova Biocare A/S, Lysaker, Norway. This company was represented in the trial steering committee for study design and the decision to submit for publication, and provided the EPAX1050TG and placebo preparations; however, the company was not involved in collection, analyses, or interpretation of the data" p. 1408 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The funding company provided the intervention and placebo preparations.</p> <p>"[...] the company was not involved in collection, analyses, or interpretation of the data" p. 1408 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"[...] the company was not involved in collection, analyses, or interpretation of the data" p. 1408 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The funding company was in involved in the decision to submit for publication. It was not part of the author team. </p> <p>1 author has received travel<br/> grants from Pronova Biocare A/S </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> <p>Rationale: data collection, analysis, presentation and interpretation seem not to be influenced by the manufacturer itself or other undue interests </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 employees of Martek Biosciences (manufacturers of DHA and inventor of a patent for DHA for treatment of AD) were involved in study concept and design </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 employees of Martek Biosciences were involved in administrative, technical or material support </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Martek employees participated in design of the study and in revision of the manuscript ("Irish Endocrine Society 34th Annual Meeting,") The statistical analysis was conducted by the Alzheimer's Disease Cooperative Study Data Core. Martek employees did not participate in the statistical analysis and did not have access to the data prior to the completion of data analysis" p. 9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 Martek employees were involved in the critical revision of the manuscript for important intellectual content. </p> <p>2 other authors were (since 2010) co‐inventors on a patent for DHA for the treatment of AD, which was filed in 2009; both waived personal rights to royalties related to this patent. Both were involved in study design and concept, supervision and acquisition of data. 1 was additionally involved in administrative, technical or material support. 1 drafted the manuscript the other was involved in its critical revision </p> <p>No other authors reported disclosures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low</p> <p>Rationale: some trial authors disclosed industry financial ties or employment in detail. However, we received all data that we had asked for and the results of the primary endpoints were reported as planned in the trials registration form. The study was otherwise accompanied by external experts and the statistical analysis seemed to be conducted independently from manufactures employees </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>The study design was "approved by an oversight committee of the National Institute on Aging. Representatives from the National Institute on Aging participated in meetings of the steering committee of the Alzheimer's Disease Cooperative Study during the course of the trial" p. 9 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nordic Natural, Watsonville, CA, USA, supplied the fish oil and placebo oil, and Meda Pharma, Bad Homburg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 from 11 authors disclosed fees for consultancy or lectures</p> <p>1 author was also involved in the ADCS‐NIA trial. He stated in the related article (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>) that he was co‐inventor on a patent for DHA for the treatment of AD but waived personal rights to royalties related to this patent </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> <p>Rationale: the study was well reported, we received all data requested and we judged the financial ties to the manufacturer as marginally </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AD: Alzheimer's disease; ADCS‐NIA: Alzheimer's Disease Cooperative Study ‐ National Institute on Aging; DHA: docosahexaenoic acid. </p> </div> </div> </section> <section id="CD009002-sec-0065"> <h4 class="title">Measures of treatment effect</h4> <p>We used mean differences (MD) or standardised mean differences (SMD) with 95% confidence intervals (CI) for continuous outcomes, and risk ratios (RR) with 95% CIs for the analysis of dichotomous outcomes. </p> <p>To date, no ranges for commonly accepted minimal clinically important differences (MCID) exist for most of the scales used to measure outcomes in people with dementia (<a href="./references#CD009002-bbs2-0055" title="Institute for Quality and Efficiency in Health Care (IQWIG). Positronenemissionstomographie (PET) und PET/CT bei Alzheimer‐Demenz. Berichtsplan Version 1.0. Available from www.iqwig.de. Köln: Institute for Quality and Efficiency in Health Care, 2013. ">IQWIG 2013</a>; <a href="./references#CD009002-bbs2-0068" title="MolnarFJ , Man‐Son‐HingM , FergussonD . Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. Journal of the American Geriatrics Society2009;57:536‐46. ">Molnar 2009</a>; <a href="./references#CD009002-bbs2-0085" title="SchragA , SchottJM , Alzheimer's Disease Neuroimaging Initiative. What is the clinically relevant change on the ADAS‐Cog?. Journal of Neurology, Neurosurgery and Psychiatry2012;83:171‐3. ">Schrag 2012</a>; <a href="./references#CD009002-bbs2-0091" title="US Preventive Task Force. Screening for cognitive impairment in older adults: final recommendation statement. AHRQ Publication No. 14‐05198‐EF‐2, 2014. www.uspreventiveservicestaskforce.org/uspstf14/dementia/dementiafinalrs.htm (accessed 31 March 2016). ">US Preventive Task Force 2014</a>; <a href="./references#CD009002-bbs2-0094" title="VellasB , AndrieuS , SampaioC , ColeyN , WilcockG . Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurology2008;7:436‐50. ">Vellas 2008</a>). We intended to present the proportion of participants with changes in the scale measures of the primary outcomes (i.e. more or less than 4 scale points for ADAS‐Cog) if data were available. However, considering the small insignificant effects, we did not request that data from the study authors. </p> <p>Scales that are commonly used in dementia trials are often coded ordinally. We treated the data measured with scales comprising of more than 10 categories as continuous variables assuming a normal distribution. </p> </section> <section id="CD009002-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the person with dementia. As defined in our protocol, we analysed only the first period of cross‐over trials considering the progressive nature of dementia. We intended to use comparable time points (± one week) for all meta‐analyses. Therefore, we conducted meta‐analyses from six‐month measurement data, which we were able to get from all trials. </p> </section> <section id="CD009002-sec-0067"> <h4 class="title">Dealing with missing data</h4> <p>We contacted trial authors requesting missing information or to clarify any remaining ambiguity. All authors replied to our queries. We received unpublished data from two trials (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>), and were able to clarify most questions with all trial authors. However, we were not able to obtain data from the OmegAD trial concerning data to adverse effects from each group (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>). We considered this issue in the appraisal of the risk of bias. </p> <p>None of the trials were able to assess the outcomes of all included participants. One trial used the last observation carried forward (LOCF) approach but did not publish the results, reasoning that the LOCF results did not differ from the per protocol analyses (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>). </p> <p>Two trials used logistic regression models to predict missing data over time (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> also presented some sensitivity analysis with multiple imputations. We described these results additionally as reported by the trial authors. </p> <p>We also considered missing data by conducting sensitivity analysis (see <a href="#CD009002-sec-0072">Sensitivity analysis</a>). </p> </section> <section id="CD009002-sec-0068"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated clinical heterogeneity and statistical heterogeneity using Chi<sup>2</sup> and I<sup>2</sup> statistics. </p> </section> <section id="CD009002-sec-0069"> <h4 class="title">Assessment of reporting biases</h4> <p>We tried to minimise reporting bias by inclusion of published and unpublished trials. Therefore, we compared conference abstracts and registered trials with published data. According to the trials registries, we found two studies that were completed but not published and contacted the responsible organisation or the researcher for more information (see <a href="#CD009002-sec-0075">Description of studies</a>). We found no further indication of unpublished trials. It was not reasonable to perform a funnel plot and Egger's test for asymmetry (<a href="./references#CD009002-bbs2-0034" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>), since we included only three trials. </p> </section> <section id="CD009002-sec-0070"> <h4 class="title">Data synthesis</h4> <p>We observed no considerable statistical heterogeneity and conducted fixed‐effect meta‐analyses to estimate an overall treatment effect. We performed all meta‐analyses by using Review Manager 5 (<a href="./references#CD009002-bbs2-0079" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We combined outcomes measured with the same scales, by presenting MDs. When different or modified scales were used to measure the same construct, we used the SMD for the meta‐analysis. A precondition for this was that the same domains (i.e. global cognitive function) or subdomain (e.g. memory) were assessed. </p> <p>Due to the progressive nature of dementia, we assumed that LOCF and per protocol analyses had a comparable distorting impact on the results. Therefore, we considered both in our meta‐analyses. </p> </section> <section id="CD009002-sec-0071"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In the protocol for this review (<a href="./references#CD009002-bbs2-0021" title="BurckhardtM , HerkeM , WustmannT , WatzkeS , LangerG , FinkA . Omega 3 fatty acids for the treatment of dementia. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009002.pub2] ">Burckhardt 2015</a>), we planned to conduct subgroup analyses of dementia subtype and stage, baseline nutritional status and dose of intervention. However, we included only three studies. All these included participants with mild to moderate AD. Analysing subgroups by the dosage was not reasonable either, because all study interventions were in a range of omega‐3 PUFAs 1.75 to 2.3 g in total. One study conducted subgroup analysis on MMSE and CDR‐SOB (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). However, they did not adjust their testing to multiple comparisons, which might bias the results. We presented the results briefly in the <a href="#CD009002-sec-0094">Effects of interventions</a> section. None of the studies conducted subgroup analysis based on nutritional status. We investigated heterogeneity in terms of participants and omega‐3 PUFA dosage. We presented the main baseline characteristics and interventions in <a href="#CD009002-tbl-0003">Table 2</a>. </p> <div class="table" id="CD009002-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of participants and main interventions of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnosis and severity of disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age (SD) (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean MMSE (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean BMI (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Use of AD medicine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily omega‐3 dose / treatment duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes relevant to this review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total 204</p> <p>IG 103</p> <p>CG 101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD</p> <p>mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.47 (8.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.41 (3.8)</p> <p>(PP population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.37 (3.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% cholinesterase inhibitors</p> <p>Memantine not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHA 1.7 g + EPA 0.6 g</p> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog</p> <p>MMSE</p> <p>CDR‐SOB</p> <p>NPI</p> <p>DAD</p> <p>MADRS</p> <p>Safety and tolerability</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>402</p> <p>IG 238</p> <p>CG 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD</p> <p>mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (8.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.66 (3.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.8% cholinesterase inhibitors</p> <p>60.4% memantine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHA 900‐1100 mg</p> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog</p> <p>CDR‐SOB</p> <p>MMSE</p> <p>ADCS‐ADL</p> <p>QoL</p> <p>NPI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> <p>IG 13</p> <p>CG 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD</p> <p>mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.55 (9.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.45 (2.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.61% cholinesterase inhibitors or memantine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>675 mg DHA</p> <p>+ 975 mg EPA</p> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog</p> <p>MMSE</p> <p>OARS‐ADL</p> <p>OARS‐IADL</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AD: Alzheimer's disease; ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; BMI: body mass index; CDR‐SOB: Clinical Dementia Rating ‐ Sum of Boxes; CG: control group; DAD: Disability Assessment for Dementia; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; IG: intervention group; MADRS: Montgomery‐Åsberg Depression rating scale; MMSE: Mini‐Mental State Examination; NPI: Neuropsychiatric Inventory; OARS‐ADL: Older Americans Resources and Services ‐ Activities of Daily Living; OARS‐IADL: Older Americans Resources and Services ‐ Instrumental Activities of Daily Living; PP: per protocol; QoL: quality of life; SD: standard deviation. </p> </div> </div> </section> <section id="CD009002-sec-0072"> <h4 class="title">Sensitivity analysis</h4> <p>We were only able to conduct our meta‐analyses by using means (or mean changes), which were observed (per protocol) or partially summarised over time (LOCF). Since dementia is a progressive disease, this might overestimate the effect in favour of omega‐3 PUFAs. As pre‐defined in our protocol, we conducted a sensitivity analysis using single imputation methods. We assumed that the mean and SD of the missing observations from both groups corresponded to those of the observed cases in the control group. For the ADAS‐Cog, we combined the assumed group results with the observed data with R statistics by using the formula for combining groups presented in Chapter 7.7. of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009002-bbs2-0049" title="HigginsJPT , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). Due to the clear results and the similarity of the trials, we did not consider it necessary to perform further sensitivity analyses including imputed data. </p> <p>We further decided to perform sensitivity analyses pooling MMSE and ADAS‐Cog results at the end of the treatment from all three trials, irrespective of study duration. </p> <section id="CD009002-sec-0073"> <h5 class="title">Presentation of results ‐ 'Summary of findings' tables</h5> <p>We used the GRADE approach to interpret the findings (<a href="./references#CD009002-bbs2-0045" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. ">Guyatt 2011</a>), and presented them in 'Summary of findings' tables as recommended by Cochrane (<a href="./references#CD009002-bbs2-0086" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). Together with our consumer group, we prioritised the above defined outcomes. </p> <p>For that purpose, we conducted a small study involving people with early dementia, their relatives, nurses, and physicians of a geriatric ward. Data collection took place from May until November 2015 in the Department of Psychiatry, Psychotherapy and Psychosomatics of the University Hospital Halle (UKH). All participants were asked to take part in this survey anonymously. A simple questionnaire presented treatment outcomes in an understandable way. We asked the recipients to mark their subjective importance of each outcome on a 9‐point Likert scale ranging from 1 (unimportant) to 9 (important). </p> <p>We collected 37 questionnaires from 14 people with dementia, 12 relatives and 11 staff members. However, in most cases the treatment goals were rated high and, therefore, resulted in a reduced variance in item scores. People with dementia, relatives and staff did not differ significantly in their evaluation, which is surely caused by the low sample size and the small variance within the ratings. In the total sample, low adverse effects of medication were rated most important, followed by enhancement of QoL, balanced state of mind, enhancement of general cognition, enhancement of memory and enhancement of instrumental activities of daily living (IADL). Enhancement of self care (ADL) was rated least important in the total sample as well as with people with dementia and relatives (see <a href="#CD009002-tbl-0004">Table 3</a>). </p> <div class="table" id="CD009002-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Prioritisation of outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome (measurement in trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>People with AD (n = 14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Relatives (n = 12)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Staff members (n = 11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total (n = 37)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Importance for decision‐making</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects of medication (number of adverse events; number of serious adverse events) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.71 (8.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.75 (1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.91 (2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.16 (1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL‐AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.57 (2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.33 (1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.09 (1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.97 (1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental health (MADRS; NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.79 (1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.00 (0.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.00 (1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.92 (1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General cognition (ADAS‐Cog; MMSE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.21 (1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.08 (1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.36 (2.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.92 (1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory (not measured)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.86 (1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.08 (1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.00 (2.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.35 (1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complex activities of daily living (i.e. shopping) (OARS‐IADL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.14 (1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.82 (1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.09 (1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.33 (1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simple activities of daily living (i.e. dressing) (ADCS‐ADL; DAD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.71 (3.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.00 (2.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.82 (1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.81 (2.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined cognition and function (CDR‐SOB)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; CDR‐SOB: Clinical Dementia Rating ‐ Sum of Boxes; DAD: Disability Assessment for Dementia; MADRS: Montgomery‐Åsberg Depression rating scale; MMSE: Mini‐Mental State Examination; n: number of participants; NPI: Neuropsychiatric Inventory; OARS‐IADL: Older Americans Resources and Services ‐ Instrumental Activities of Daily Living; QoL‐AD: Quality of Life Alzheimer's Disease; SD: standard deviation. </p> </div> </div> <p>We imported data of the meta‐analyses by using the GRADEpro GDT to create 'Summary of findings' tables. These included for each outcome: the estimate of the treatment effect, the quantity of supporting evidence and the quality of that evidence assessed using the GRADE approach (<a href="./references#CD009002-bbs2-0045" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395‐400. ">Guyatt 2011</a>). Two review authors (MB and GL) used the recommended approach to downgrade the evidence from 'high quality' by one level for serious (or by two for very serious) study limitations (risk of bias), indirectness of evidence, serious inconsistency, imprecision of effect estimates or potential publication bias. </p> <p>We included the outcomes in the 'Summary of findings' tables in the order that our consumer group prioritised them (<a href="#CD009002-tbl-0004">Table 3</a>). We did not ask for global measurements that included cognition and function. However, cognition and function were both rated as critical treatment goals. Therefore, we included results of the CDR‐SOB as well. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009002-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009002-sec-0074"></div> <section id="CD009002-sec-0075"> <h3 class="title">Description of studies</h3> <section id="CD009002-sec-0076"> <h4 class="title">Results of the search</h4> <p>The electronic searches from March and December 2015 retrieved 3064 results. After de‐duplication by Anna Noel‐Storr, Trials Search Coordinator of the CDCIG, two review authors (MB and MH or MB and AF) independently assessed the remaining 2331 references for relevance. We identified one further reference by scanning the reference lists of landmark papers and included studies. We received no information for further published or unpublished studies by experts or manufacturers. We discarded 2299 references that were not relevant. Two review authors (MB and MH) independently assessed 31 articles and conference abstracts for eligibility. Seven articles and two registered trials did not meet our inclusion criteria (see <a href="./references#CD009002-sec-0124" title="">Characteristics of excluded studies</a> table). We included 24 articles referring to three trials (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>; <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). The selection process is presented in the PRISMA statement (<a href="./references#CD009002-bbs2-0059" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Journal of Clinical Epidemiology2009;62(10):e1‐34. ">Liberati 2009</a>) (see <a href="#CD009002-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD009002-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009002-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009002-sec-0077"> <h4 class="title">Included studies</h4> <p>Three trials met the inclusion criteria for this review (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>; <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>), and 632 participants were randomised in total. Clinically, the included studies were comparable with respect to the participants (mild to moderate AD) and dosage of the intervention (EPA plus DHA between 1750 and 2300 mg/day). The mean values of nutritional parameters presented in the studies, indicated no malnutrition, lack of DHA or other relevant baseline characteristics (<a href="#CD009002-tbl-0003">Table 2</a>). The trials had a considerable variation in duration. For most of the primary and secondary outcomes, the trial authors sent us the results from six months' follow‐up, which we combined in meta‐analyses. Statistically, we observed no relevant heterogeneity by using Chi<sup>2</sup> and I<sup>2</sup> statistics. </p> <p>The largest trial investigated omega‐3 PUFAs in a parallel‐group design over a study period of 18 months with the primary aim of cognitive and functional outcomes (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). It was sponsored by the Alzheimer's Disease Cooperative Study (ADCS) in co‐operation with the National Institute of Aging (NIA) and DSM Nutritional Products. DSM Nutritional Products is a leading supplier of nutritional supplements. The trial is also referred to as the ADCS‐NIA trial. Dr. Joseph Quinn provided some unpublished data (<a href="#CD009002-tbl-0005">Table 4</a>). </p> <div class="table" id="CD009002-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Unpublished data from the ADCS trials (total scores, provided via personal communication)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Measurement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>6 months' follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>18 months' follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Linear mixed‐effects model at 18 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Omega‐3 PUFA mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p><b>mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Omega‐3 PUFA</b> </p> <p><b>mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p><b>mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Omega‐3 PUFA</b> </p> <p><b>mean (SD)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.96 (9.21)</p> <p>n = 162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.77 (8.87)</p> <p>n = 236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.73<br/> (10.7) </p> <p>n = 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.53<br/> (11.07) </p> <p>n = 217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.53<br/> (14.57)<br/> n = 128 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.17<br/> (14.76) </p> <p>n = 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADCS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.68 (12.9)</p> <p>n= 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.12 (12.32)</p> <p>n = 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8<br/> (15.43) </p> <p>n = 147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.55<br/> (14.94) </p> <p>n = 219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDR‐SOB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.77<br/> (2.61) </p> <p>n = 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.61 (2.62)</p> <p>n = 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.75<br/> (3.16) </p> <p>n = 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.86<br/> (3.3) </p> <p>n = 216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.15 (10.83)</p> <p>n = 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.92 (10.37)</p> <p>n = 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.58</p> <p>(10.8)</p> <p>n = 146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.17</p> <p>(12.47)</p> <p>n = 219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL‐AD informant rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.96 (6.13)</p> <p>n = 151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.45 (5.78)</p> <p>n = 220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.31 (5.82)</p> <p>n = 136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.55 (5.84)</p> <p>n = 195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.91 (6.3)</p> <p>n = 120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.42 (5.95)</p> <p>n = 162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL‐AD participant rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.43 (5.38)</p> <p>n = 150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0 (4.84)</p> <p>n = 222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.86 (5.41)</p> <p>n = 133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.76 (5.33)</p> <p>n = 199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.02 (6.09)</p> <p>n = 119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.63 (5.45)</p> <p>n = 150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.66</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; CDR‐SOB: Clinical Dementia Rating ‐ Sum of Boxes; n: number of participants; NPI: Neuropsychiatric Inventory; PUFA: polyunsaturated fatty acid; QoL‐AD: Quality of Life Alzheimer's Disease; SD: standard deviation. </p> <p><sup>a</sup>For ADAS‐Cog missing items imputed with last observation carried forward; missing total scores not imputed. </p> </div> </div> <p>The second largest trial, named the OmegAD study, was a cross‐over design trial of 12 months' duration sponsored by the Karolinska University Hospital in Sweden (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>). The primary aim was to test efficacy of omega‐3 PUFAs on cognition. We included the results of the first period after a follow‐up of six months. </p> <p>The third trial was a small pilot study with a three‐arm parallel design (<a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). Its primary aim was to evaluate the effects of omega‐3 PUFAs alone or in combination with alpha lipoic acid on oxidative stress parameters. We included the study's secondary, but patient‐relevant, outcomes on the comparison of omega‐3 PUFA versus placebo. Dr. Lynne Shinto provided unpublished six months data (<a href="#CD009002-tbl-0006">Table 5</a>), which we used for the meta‐analyses. The trial lasted 12 months and was sponsored by the Oregon Health and Science University in the USA and conducted in collaboration with NIA and the National Center for Complementary and Integrative Health (NCCIH). </p> <div class="table" id="CD009002-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Unpublished data as provided via personal communication by Dr. Shinto</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Measurement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>6 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo mean (SD) n = 11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Omega mean (SD) n = 12</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.10 (6.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.8 (9.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.4 (4.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 (4.4)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; MMSE: Mini‐Mental State Examination; n: number of participants; SD: standard deviation. </p> </div> </div> <p>In addition to the <a href="./references#CD009002-sec-0123" title="">Characteristics of included studies</a> table, we presented an overview of the main baseline characteristics, interventions and outcomes of all three studies in <a href="#CD009002-tbl-0003">Table 2</a>. </p> <p>We did not identify any trials investigating omega‐3 PUFAs in people with other types of dementia. We also found no trials investigating diets enriched with omega‐3 PUFAs. </p> <section id="CD009002-sec-0078"> <h5 class="title">Participants</h5> <p>The number of randomised men and women ranged from 26 to 402 with a range of mean age from 73.5 to 76 years. All trials were restricted to people with AD diagnosed with established criteria according to the Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV: <a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>) or NINCDS‐ADRDA criteria (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). The severity of the disease was mild to moderate ranging from an MMSE of 23.6 (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>) down to 20.66 (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>), and the majority of the participants received a stable dose of cholinesterase inhibitors or memantine. All trials defined pre‐study intake of omega‐3 supplements as an exclusion criterion. The ADCS‐NIA trial also excluded participants who consumed on average DHA more than 200 mg/day in the form of food (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). </p> <p>Two of the trials took place in the USA (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>), and one in Sweden (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>). All three trial were conducted in outpatient care. The baseline data showed no indication of poor nutrition. The mean body mass index ranged from 24 (SD 3) (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>) to 26 (SD 4) (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). The baseline data from the blood samples indicated a sufficient intake of omega‐3 PUFAs. <a href="#CD009002-tbl-0003">Table 2</a> presents the most relevant baseline characteristics of all three trials in detail. </p> </section> <section id="CD009002-sec-0079"> <h5 class="title">Interventions</h5> <p>All participants received omega‐3 PUFAs as 1 g capsules containing various amounts of omega‐3 PUFAs versus placebo. In the OmegAD trial, participants consumed the highest dose of omega‐3 PUFAs with a combination of DHA 1.7 g and EPA 0.6 g (derived from fish oil) provided in four capsules per day (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>). The capsules further contained vitamin E (tocopherol) 4 mg as a preservative. In the ADCS‐NIA trial, two capsules of an algal‐derived DHA were provided daily (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). This vegetarian source of omega‐3 PUFAs contained no EPA but approximately 45% to 55% of DHA by weight. This means that the participants received a daily dose of around DHA 900 to 1100 mg daily. In the trial of <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>, participants were recommended to ingest three lemon‐flavoured fish oil concentrate capsules with food. The daily dose contained DHA 675 mg and EPA 975 mg. All trials analysed blood samples for serum fatty acid levels, which increased significantly compared to unchanged levels in placebo groups; this can be interpreted as good compliance for the intervention. </p> </section> <section id="CD009002-sec-0080"> <h5 class="title">Outcome measures</h5> <p>The trials used the following outcome measures. <a href="#CD009002-tbl-0003">Table 2</a> summarises their use in the included studies. For a better interpretation, we presented related estimates of clinical important changes as identified in the literature. Appropriate methods for defining valid estimates of MCIDs are not yet fully developed and for scales, covering different constructs (i.e. global severity scales), almost impossible to determine (<a href="./references#CD009002-bbs2-0068" title="MolnarFJ , Man‐Son‐HingM , FergussonD . Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. Journal of the American Geriatrics Society2009;57:536‐46. ">Molnar 2009</a>). Furthermore, what is estimated to be a clinically important difference depends on the population (i.e. severity of dementia) and contextual characteristics (i.e. ratio of adverse effects and efficacy) and might vary from different points of view (i.e. researcher or participant) (<a href="./references#CD009002-bbs2-0078" title="RevickiD , HaysR D , CellaD , SloanJ . Recommended methods for determining responsiveness and minimally important differences for patient‐reported outcomes. Journal of Clinical Epidemiology2008;61(2):102‐9. ">Revicki 2008</a>). This also applies to the following presented estimates of clinical important changes. They were developed with varying methods and address different circumstances and disease severity. Therefore, they should be considered with caution. </p> <section id="CD009002-sec-0081"> <h6 class="title">Global and specific cognitive function cognitive function measures</h6> <p> <ul id="CD009002-list-0011"> <li> <p>Mini‐Mental State Examination (MMSE) evaluates severity and progression of cognitive impairment in the five areas of orientation, immediate recall, attention and calculation, delayed recall, and language (<a href="./references#CD009002-bbs2-0041" title='FolsteinMF , FolsteinSE , McHughPR . "Mini‐mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12:189‐98. '>Folstein 1975</a>). The test score ranges from 0 to 30 with higher scores representing better cognitive function. The severity of cognitive impairment is usually classified by MMSE score points such as 20/21 to 26/27 as mild, 10 to 19/20 as moderate, and less than 10 as severe impaired (<a href="./references#CD009002-bbs2-0053" title="HulstaertF , ThiryN , EyssenM , VrijensF . Pharmaceutical and non‐pharmaceutical interventions for Alzheimer's Disease, a rapid assessment. Brussels: Belgian Health Care Knowledge Centre (KCE), 2009. ">Hulstaert 2009</a>). MCIDs of 1.4 to 3.7 score points are commonly estimated (corresponds to the estimates of <a href="./references#CD009002-bbs2-0020" title="BurbackD , MolnarFJ , StJohnP , Man‐Son‐HingM . Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Dementia and Geriatric Cognitive Disorders1999;10:534‐40. ">Burback 1999</a>; <a href="./references#CD009002-bbs2-0048" title="HenselA , AngermeyerMC , Riedel‐HellerSG . Measuring cognitive change in older adults: reliable change indices for the Mini‐Mental State Examination. Journal of Neurology, Neurosurgery and Psychiatry2007;78(12):1298‐303. ">Hensel 2007</a>; <a href="./references#CD009002-bbs2-0075" title="QaseemA , SnowV , CrossJTJr , ForcieaMA , HopkinsRJr , ShekelleP , et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Annals of Internal Medicine2008;148(5):370‐8. [PUBMED: 18316755] ">Qaseem 2008</a>). </p> </li> </ul> <ul id="CD009002-list-0012"> <li> <p>The Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog) comprises spoken language ability, comprehension of spoken language, recall of test instructions, word finding difficulty, following commands, naming objects, construction drawing, ideational praxis, orientation, word recall and word recognition. The score ranges from 0 to 70, with a higher score indicating a greater impairment (<a href="./references#CD009002-bbs2-0082" title="RosenWG , MohsRC , DavisKL . A new rating scale for Alzheimer's disease. American Journal of Psychiatry1984;141:1356‐64. ">Rosen 1984</a>). MCID is mainly estimated between 2 and 4 score points (<a href="./references#CD009002-bbs2-0054" title="HuntleyJD , GouldRL , LiuK , SmithM , HowardRJ . Do cognitive interventions improve general cognition in dementia? A meta‐analysis and meta‐regression. BMJ Open2015;5(4):e005247. [PUBMED: 25838501] ">Huntley 2015</a>; <a href="./references#CD009002-bbs2-0068" title="MolnarFJ , Man‐Son‐HingM , FergussonD . Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. Journal of the American Geriatrics Society2009;57:536‐46. ">Molnar 2009</a>; <a href="./references#CD009002-bbs2-0085" title="SchragA , SchottJM , Alzheimer's Disease Neuroimaging Initiative. What is the clinically relevant change on the ADAS‐Cog?. Journal of Neurology, Neurosurgery and Psychiatry2012;83:171‐3. ">Schrag 2012</a>; <a href="./references#CD009002-bbs2-0094" title="VellasB , AndrieuS , SampaioC , ColeyN , WilcockG . Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurology2008;7:436‐50. ">Vellas 2008</a>). The OmegAD trial used an extended version of the ADAS‐Cog (scale range 0 to 85) (<a href="./references#CD009002-bbs2-0065" title="MohsRC , KnopmanD , PetersenRC , FerrisSH , ErnestoC , GrundmanM , et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders1997; Vol. 11, issue Suppl 2. ">Mohs 1997</a>). </p> </li> <li> <p>None of the studies presented specific cognitive function measures (i.e. memory).</p> </li> </ul> </p> </section> <section id="CD009002-sec-0082"> <h6 class="title">Functional outcome measures (e.g. activities of daily living)</h6> <p> <ul id="CD009002-list-0013"> <li> <p>The Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living (ADCS‐ADL) was specifically designed as part of a comprehensive test battery to assess ADL living in people with AD in clinical trials (<a href="./references#CD009002-bbs2-0042" title="GalaskoD , BennettD , SanoM , ErnestoC , ThomasR , GrundmanM , et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease &amp; Associated Disorders1997;11(Suppl 2):33‐9. ">Galasko 1997</a>). It consists of 23 criteria comprising simple everyday skills and complex activities, which are rated based on an interview with an informant who knows the affected study participant well. The range is from 0 to 78 with a higher score indicating a lower interference. Data on MCID for ADCS‐ADL are limited. One study group defined a threshold of a 2 point score change as meaningful in an RCT investigating vitamin E and memantine in mild to moderate AD (<a href="./references#CD009002-bbs2-0031" title="DyskenMW , SanoM , AsthanaS , VertreesJ E , PallakiM , LlorenteM , et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM‐AD VA cooperative randomized trial. JAMA2014;311(1):33‐44. ">Dysken 2014</a>). </p> </li> </ul> <ul id="CD009002-list-0014"> <li> <p>The Disability Assessment for Dementia (DAD) evaluates the performance of daily function in community‐dwelling people with dementia based on carer information (<a href="./references#CD009002-bbs2-0043" title="GelinasI , GauthierL , McIntyreM , GauthierS . Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. American Journal of Occupational Therapy1999;53(5):471‐81. ">Gelinas 1999</a>). The instrument evaluates initiation, planning and execution of simple and complex activities. A final score is formed by a percentage of all questions rated positive, indicating that the study participant is able to perform the respective task without help. Therefore, lower scores indicate more dysfunction. We found no estimates of a meaningful change. </p> </li> <li> <p>The Older Americans Resources and Services ‐ Activities of Daily Living (OARS‐ADL) Questionnaire (<a href="./references#CD009002-bbs2-0039" title="FillenbaumGG . OARS multidimensional functional assessment questionnaire complete activities of daily living section (ADL, IADL, Summary Scale), 1975. www.dementia‐assessment.com.au/symptoms/oars_adl_iadl.pdf (accessed 31 March 2016). ">Fillenbaum 1975</a>; <a href="./references#CD009002-bbs2-0044" title="GeorgeLK , FillenbaumGG . OARS methodology. A decade of experience in geriatric assessment. Journal of the American Geriatrics Society1985;33(9):607‐15. [PUBMED: 4031339] ">George 1985</a>) is a part of a multidimensional functional assessment (<a href="./references#CD009002-bbs2-0040" title="FillenbaumGG , SmyerMA . The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. Journal of Gerontology1981;36(4):428‐34. [PUBMED: 7252074] ">Fillenbaum 1981</a>). According to Dr. Shinto (personal communication), the pilot trial used a modified version with score ranges from 0 to 27 for ADL and 0 to 14 for IADL (<a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). A lower score indicates a better function. We found no estimates of a meaningful change. </p> </li> </ul> </p> </section> <section id="CD009002-sec-0083"> <h6 class="title">Overall dementia severity measures</h6> <p> <ul id="CD009002-list-0015"> <li> <p>The Clinical Dementia Rating ‐ Sum of Boxes (CDR‐SOB) is a semi‐structured interview of people with dementia and informants for the assessment of cognition (memory, orientation, judgement/problem solving) and function (community affairs, home/hobbies, personal care) (<a href="./references#CD009002-bbs2-0074" title="O'BryantSE , WaringSC , CullumCM , HallJ , LacritzL , MassmanPJ , et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's Research Consortium study. Archives of Neurology2008;65(8):1091‐5. ">O'Bryant 2008</a>). The CDR‐SOB total score ranges from 0 to 18 with scores around 3 to 15.5 indicating mild to moderate dementia (<a href="./references#CD009002-bbs2-0074" title="O'BryantSE , WaringSC , CullumCM , HallJ , LacritzL , MassmanPJ , et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's Research Consortium study. Archives of Neurology2008;65(8):1091‐5. ">O'Bryant 2008</a>). A Clinical Dementia Rating ‐ Global score can be derived from the box scores. We found no estimates of a meaningful change. </p> </li> </ul> </p> </section> <section id="CD009002-sec-0084"> <h6 class="title">Measures of symptoms associated with dementia</h6> <p> <ul id="CD009002-list-0016"> <li> <p>The Montgomery‐Åsberg Depression Rating Scale (MADRS) is a measure of mental health and was particularly developed to assess change secondary to treatment of depressive symptoms (<a href="./references#CD009002-bbs2-0069" title="MontgomerySA , AsbergM . A new depression scale designed to be sensitive to change. British Journal of Psychiatry1979;134:382‐9. ">Montgomery 1979</a>). The scale encompasses 10 symptoms associated with depression (i.e. sadness or tension), the seriousness of which are rated by a clinician based on observation or reporting after an interview. The total score ranges from 0 to 60, higher scores indicating more severe symptoms. The cut‐off point for mild depression is usually at 13 points (<a href="./references#CD009002-bbs2-0073" title="Müller‐ThomsenT , ArltS , MannU , MaßR , GanzerS . Detecting depression in Alzheimer's disease: evaluation of four different scales. Archives of Clinical Neuropsychology2005;20:271‐6. ">Müller‐Thomsen 2005</a>). MCID estimates range from 1 to 2 points in people with depressive symptoms (<a href="./references#CD009002-bbs2-0030" title="DuruG , FantinoB . The clinical relevance of changes in the Montgomery‐Åsberg Depression Rating Scale using the minimum clinically important difference approach. Current Medical Research and Opinion2008;24(5):1329‐35. [DOI: 10.1185/030079908X291958] ">Duru 2008</a>). </p> </li> </ul> <ul id="CD009002-list-0017"> <li> <p>The 10‐item Neuropsychiatric Inventory (NPI) evaluates neuropsychiatric disturbance common in dementia and associated with mental health: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy and aberrant motor activity (<a href="./references#CD009002-bbs2-0025" title="CummingsJL , MegaM , GrayK , Rosenberg‐ThompsonS , CarusiD A , GornbeinJ . The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology1994;44(12):2308‐14. ">Cummings 1994</a>). Scores range from 0 (normal) to 120 (severely disturbed). The 12‐item extension also assesses night‐time behavioural disturbances, appetite and eating abnormalities (score range 0 to 144) (<a href="./references#CD009002-bbs2-0026" title="CummingsJL . The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology1997;48(5 Suppl 6):S10‐6. ">Cummings 1997</a>). The information is obtained from a person familiar with the patient's behaviour. A change of 4 to 8 points is suggested to be clinically meaningful (<a href="./references#CD009002-bbs2-0027" title="CummingsJ . Neuropsychiatric Inventory (NPI) setting the standard for Alzheimer research: FAQs. npitest.net/faqs.html (accessed 31 March 2016). ">Cummings 2015</a>; <a href="./references#CD009002-bbs2-0052" title="HowardR , PhillipsP , JohnsonT , O'BrienJ , SheehanB , LindesayJ , et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry2011;26(8):812‐7. ">Howard 2011</a>). </p> </li> </ul> </p> </section> <section id="CD009002-sec-0085"> <h6 class="title">Measures of quality of life</h6> <p> <ul id="CD009002-list-0018"> <li> <p>The Quality of Life Alzheimer's Disease scale (QoL‐AD) exists in two versions both for people with AD (self reported) and their informal carers (proxy reported). QoL is assessed in 13 items, covering physical health, energy, mood, memory, living and financial situation, relationships to life partner, family and friends, the ability to perform household and leisure activities, and judgements of one's self and life as a whole. The total score ranges from 13 to 52 points with a higher score reflecting a better QoL (<a href="./references#CD009002-bbs2-0061" title="LogsdonRG , GibbonsLE , McCurrySM , TeriL . Assessing quality of life in older adults with cognitive impairment. Psychosomatic Medicine2002;64(6):510‐9. ">Logsdon 2002</a>). We found no estimates of an MCID. </p> </li> </ul> </p> </section> <section id="CD009002-sec-0086"> <h6 class="title">Adverse events</h6> <p> <ul id="CD009002-list-0019"> <li> <p>Safety and tolerability was a secondary outcome in <a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> but it was not reported in detail which parameters were assessed and how they were measured. The two other trials did not name adverse events explicitly as an outcome but presented the most reported adverse events. They were either reported by the study participants or partners (<a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>), or it was not clear how they were assessed (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>; <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). Serious adverse events, as normally assessed by data and safety monitoring, were in the ADCS‐NIA trial defined as "...events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). </p> </li> </ul> </p> <p>Some secondary outcomes as defined in the protocol of this review (<a href="./references#CD009002-bbs2-0021" title="BurckhardtM , HerkeM , WustmannT , WatzkeS , LangerG , FinkA . Omega 3 fatty acids for the treatment of dementia. Cochrane Database of Systematic Reviews2015, Issue 3. [DOI: 10.1002/14651858.CD009002.pub2] ">Burckhardt 2015</a>), such as compliance with intervention, entry to institutional care, hospital admissions and mortality, were not assessed explicitly as outcomes in any of the trials. We considered the themes in the adverse events and tolerability section. </p> <p><a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> published score changes from baseline adjusted for baseline MMSE. If five or fewer items were missing on ADAS‐Cog, those items where imputed based on LOCF methods, on a per item, per participant basis. Missing score measures over time were predicted by linear mixed‐effects (LME) regression models. In a sensitivity analysis, they used analysis of covariance (ANCOVA) methods using multiple imputation methods. Dr. Quinn provided us with unpublished total mean values and QoL data, which were used in the meta‐analyses. </p> <p><a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> also published score changes analysed with LME model. They adjusted for age and education. Dr. Shinto sent us total mean values from six months' follow‐up, which we used for the meta‐analyses. </p> <p><a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> presented data as observed by presenting MDs. They also performed an LOCF analysis and stated that the results were comparable. </p> </section> </section> </section> <section id="CD009002-sec-0087"> <h4 class="title">Excluded studies</h4> <p>We excluded eight publications and two registered trials and presented the reasons in the <a href="./references#CD009002-sec-0124" title="">Characteristics of excluded studies</a> table. The main reasons for exclusion were a duration of intervention of less than 26 weeks (<a href="./references#CD009002-bbs2-0005" title="ChiuC‐C , SuK‐P , ChengT‐C , LiuH‐C , ChangC‐J , DeweyME , et al. The effects of omega‐3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double‐blind placebo‐controlled study. Progress in Neuro‐psychopharmacology &amp; Biological Psychiatry2008;32:1538‐44. ">Chiu 2008</a>), inclusion of participants other than people with dementia (<a href="./references#CD009002-bbs2-0008" title="HashimotoM , YamashitaK , KatoS , TamaiT , MitaraiM , MatsumotoI , et al. Beneficial effects of daily dietary omega‐3 polyunsaturated fatty acid supplementation on age‐related cognitive decline in elderly Japanese with very mild dementia: a 2‐year randomized, double‐blind, placebo‐controlled trial. Journal of Aging Research &amp; Clinical Practice2012;1(3):193‐201. ">Hashimoto 2012</a>; <a href="./references#CD009002-bbs2-0009" title="MahmoudiMJ , HedayatM , SharifiF , MirarefinM , NazariN , MehrdadN , et al. Effect of low dose ‐3 poly unsaturated fatty acids on cognitive status among older people: a double‐blind randomized placebo‐controlled study. Journal of Diabetes &amp; Metabolic Disorders2014;13:34. ">Mahmoudi 2014</a>), or different study design (<a href="./references#CD009002-bbs2-0011" title="TeranoT , FujishiroS , BanT , YamamotoK , TanakaT , NoguchiY , et al. Docosahexaenoic acid supplementation improves the moderately severe dementia from thrombotic cerebrovascular diseases. Lipids1999;34 Suppl:S345‐6. ">Terano 1999</a>). According to the trials registries, we found two studies that were completed but not published. We then contacted the responsible organisation or the researcher. The North East London NHS Foundation Trust (UK) wrote to us, that their trial was not completed due to non‐significant results and low numbers recruited (<a href="./references#CD009002-bbs2-0004" title="CarterJ . A randomised placebo‐controlled trial of polyunsaturated omega‐3 fatty acid (PFA), in the treatment of dementia; a pilot study, 2006. www.isrctn.com/ISRCTN27372325 (accessed 31 March 2016). ">Carter 2006</a>). The sponsor (NeuroBioPharm Inc) of the other registered trial informed us that the company was "unable to share any information" with us at this time (<a href="./references#CD009002-bbs2-0010" title="NCT00867828 . Multi‐center, double‐blind, placebo‐controlled, monotherapy study of Neptune Krill Oil (NKO™) in early stage Alzheimer's disease, 2009. clinicaltrials.gov/show/NCT00867828 (accessed 31 March 2016). ">NCT00867828</a>). However, with a planned duration of treatment of 24 weeks, the trial does most appear to fulfil our inclusion criteria. </p> </section> </section> <section id="CD009002-sec-0088"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, we judged the quality of the trials as high (<a href="#CD009002-fig-0001">Figure 1</a>). There were only a few uncertainties (see <a href="./references#CD009002-sec-0123" title="">Characteristics of included studies</a> table), which we do not think have an important influence on the overall results. </p> <section id="CD009002-sec-0089"> <h4 class="title">Allocation</h4> <p>All trial authors provided details of adequate sequence generation describing computer‐generated schemes (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> (reported in Faxen‐Irving 2009); <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). </p> </section> <section id="CD009002-sec-0090"> <h4 class="title">Blinding</h4> <p>All three trials used adequate blinding methods for participants by using placebo capsules with an identical appearance. Capsules were usually swallowed whole, therefore, we did not judge it as bias that only one trial team made efforts to match the fish‐like smell of omega‐3 PUFAs in their placebo capsules (<a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). </p> <p>The reports of <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> and <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> indicated that outcome assessors were blinded during the whole study duration. However, it was not clear in the OmegAD study (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>) if blinding was maintained long enough to blind the outcome assessor. </p> </section> <section id="CD009002-sec-0091"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> and <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> presented numbers and reasons for participants who withdrew or dropped out. Numbers and reasons were similar in intervention and control groups. They included missing data by LMEs models. </p> <p>In the OmegAD trial, an intention‐to‐treat (ITT) analysis on the basis of LOCF was carried out but not published, reasoning that there were no differences to the per‐protocol analysis (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>). </p> </section> <section id="CD009002-sec-0092"> <h4 class="title">Selective reporting</h4> <p>Overall, we judged the bias for selective reporting as low. The trials analysed and presented all primary outcomes as described in the published trial protocols. We received data to further outcomes as requested. Secondary outcomes and subgroup analysis of <a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> and <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> were not congruent in detail with the published trial protocols, but there was no indication of favourable reporting of outcomes relevant to this review. However, there were some inconsistencies with reporting of adverse events. <a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> presented the reasons for participants leaving the study but not in regard to their group affiliation. We were not able to get this information by mail contact with Dr. Freund‐Levy. Even though these incidents were low in numbers, it cannot be excluded that this might favour omega‐3 PUFAs. </p> </section> <section id="CD009002-sec-0093"> <h4 class="title">Other potential sources of bias</h4> <p>Omega‐3 suppliers provided all study drugs. <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> reported having no further conflicts of interest. </p> <p>A company producing omega‐3 PUFAs partly funded the OmegAD trial (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>). An omega‐3 supplier was also involved as a collaborator in the ADCS‐NIA trial (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). Both trial authors reported that industry was involved in study design and the submission of the publication. Apart from that, they reported only minor conflicts of interest. However, authors of both trials explicitly state that industry was not involved in collection and analysis of study data, which, in our view, is the most vulnerable part of a trial (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>; <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). Considering this and the transparent reporting of all pre‐defined results, we do not judge the reported co‐operation with industry as a relevant source of bias. However, a possible influence of industry in presenting results cannot be ruled out with certainty. </p> <p>We do not regard any imbalance of baseline data as relevant for the outcomes of this review. Furthermore, none of the studies stopped earlier than planned in the published protocol. </p> </section> </section> <section id="CD009002-sec-0094"> <h3 class="title" id="CD009002-sec-0094">Effects of interventions</h3> <p>See: <a href="./full#CD009002-tbl-0001"><b>Summary of findings for the main comparison</b> Omega‐3 PUFA supplements compared to placebo for people with mild to moderate Alzheimer's disease</a> </p> <p>There was no therapeutic benefit for all outcomes in people with mild to moderate AD. This result was irrespective of the omega‐3 PUFAs dose, which was between 1.75 and 2.3 g/day. For the meta‐analyses that we conducted for this review, we used published per‐protocol data from the OmegAD trial (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>), and unpublished data that we received from Dr. Quinn (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>) and Dr. Shinto (<a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). </p> <p>None of the trials observed any significant effect on any of the outcomes relevant for this review. Therefore, we have largely refrained from presenting all of the effect measures and CIs separately. This especially applies to the pilot trial of <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>, which did not have enough power to detect a difference in any outcomes relevant to people with AD. We presented results of all outcomes separately. </p> <section id="CD009002-sec-0095"> <h4 class="title">Changes in global and specific cognitive function (primary outcomes)</h4> <p><a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>, <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>, and <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> assessed the cognitive function with MMSE and ADAS‐Cog. </p> <p>There was no evidence of a benefit for omega‐3 PUFAs compared to placebo in any of the studies. A meta‐analysis based on <a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> and <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> showed no effect on cognition when measured with MMSE at six months (MD 0.18, 95% CI ‐1.05 to 1.41; 202 participants; 2 studies; I<sup>2</sup> = 0%). We graded the quality of evidence across the studies as high (<a href="./full#CD009002-tbl-0001">summary of findings Table for the main comparison</a>). <a href="#CD009002-fig-0003">Figure 3</a> shows the meta‐analysis (<a href="./references#CD009002-fig-0007" title="">Analysis 1.1</a>). </p> <div class="figure" id="CD009002-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Omega‐3 PUFAs versus placebo for mild to moderate Alzheimer's disease. Analysis 1.1 Mini‐Mental State Examination (MMSE; 6 months' follow‐up, PP analysis)." data-id="CD009002-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Omega‐3 PUFAs versus placebo for mild to moderate Alzheimer's disease. Analysis 1.1 Mini‐Mental State Examination (MMSE; 6 months' follow‐up, PP analysis). </p> </div> </div> </div> <p><a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> assessed cognition with MMSE at a follow‐up of 18 months in an ANCOVA analysis that showed no difference between groups (P value = 0.88). This was consistent with <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> where there was no difference (P value = 0.80) at 12 months in an LME model when adjusted for age and education level. </p> <p>This result also applied for cognition measured with ADAS‐Cog. We performed a meta‐analysis of six months' data of all trials, which revealed no significant benefit for omega‐3 PUFAs (SMD ‐0.02, 95% CI ‐0.19 to 0.15; 566 participants; 3 studies; I<sup>2</sup> = 0%) (<a href="./references#CD009002-fig-0008" title="">Analysis 1.2</a>). We judged the quality of evidence across the studies as high (<a href="./full#CD009002-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>In the ADCS trial, there was no significant difference observed at 18 months' follow‐up when missing data were considered with an LME model (P value = 0.41) adjusted for baseline MMSE or in an ANCOVA with data after multiple imputation (P value = 0.99; unpublished data) (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). </p> <p>None of the included trials assessed specific cognitive functions.</p> </section> <section id="CD009002-sec-0096"> <h4 class="title">Changes in functional outcome measures (e.g. activities of daily living (primary outcome))</h4> <p>A meta‐analysis with functional measures on DAD (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>) and ADCS‐ADL (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>) showed no difference at six months (SMD ‐0.02, 95% CI ‐0.19 to 0.16; 544 participants; 2 studies; I<sup>2</sup> = 23%) (<a href="./references#CD009002-fig-0009" title="">Analysis 1.3</a>; <a href="#CD009002-fig-0004">Figure 4</a>). We rated the quality of evidence across the studies as high (<a href="./full#CD009002-tbl-0001">summary of findings Table for the main comparison</a>). </p> <div class="figure" id="CD009002-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Omega‐3 PUFAs versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Analysis 1.3 Activities of daily living (6 months' follow‐up, PP analysis). ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; DAD: Disability Assessment for Dementia." data-id="CD009002-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Omega‐3 PUFAs versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Analysis 1.3 Activities of daily living (6 months' follow‐up, PP analysis). ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; DAD: Disability Assessment for Dementia. </p> </div> </div> </div> <p>Considering missing data in LME models, this result was consistent when ADL was measured on a modified version of the OARS at 12 months (P value = 0.82) (<a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>), or on the ADCS‐ADL at 18 months (P value = 0.38) (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). </p> <p><a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> observed a significant difference for IADL measured on the OARS‐IADL subscale in favour for omega‐3 PUFAs at 12 months (MD ‐3.50, 95% CI ‐4.30 to ‐2.70; 22 participants) (<a href="./references#CD009002-fig-0010" title="">Analysis 1.4</a>). When missing data were considered in an LME model adjusting for age and education at 12 months, the result remained positive in favour for omega‐3 PUFAs (P value &lt; 0.01) (<a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). Although the difference was significant, the outcome was only presented by one very small study. We downgraded the quality of evidence to moderate because of a wide CI and a very low number of participants (<a href="./full#CD009002-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD009002-sec-0097"> <h4 class="title">Overall dementia severity (primary outcome)</h4> <p>A meta‐analysis including measures of CDR‐SOB from two studies revealed no significant difference between omega‐3 PUFAs and placebo at six months (MD ‐0.00, 95% CI ‐0.58 to 0.57; 542 participants; 2 studies; I<sup>2</sup> = 0%) (<a href="./references#CD009002-fig-0011" title="">Analysis 1.5</a>) (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>; <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). We graded the quality of evidence across the studies as high. The result was consistent in an LME model at 18 months (P value = 0.68) (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). </p> </section> <section id="CD009002-sec-0098"> <h4 class="title">Adverse effects (primary outcome)</h4> <p>The European Medicines Agency (EMA) recommends an on‐treatment follow‐up of at least 12 months to demonstrate long‐term safety (<a href="./references#CD009002-bbs2-0035" title="European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. EMA/CHMP/539931/2014 Corr. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176827.pdf (accessed 23 October 2014). ">EMA 2014</a>). <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> and <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> fulfilled these requirements by implementing a treatment duration of 12 (<a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>) and 18 (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>) months. <a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> did not report adverse events in detail. </p> <p>Two of the three included studies described the intervention as well tolerated and with only mild adverse events (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). In the study of <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>, adverse events such as cold or influenza (omega‐3 PUFAs: 2/13; placebo: 2/13), loose stools (omega‐3 PUFAs: 2/13; placebo: 3/13), dizziness (omega‐3 PUFAs: 1/13; placebo: 2/13) or falls (omega‐3 PUFAs: 1/13: placebo: 2/13) were similar between treatment and placebo group. Serious adverse events (omega‐3 PUFAs: 1/13 (cardiac arrest); placebo: 1/13 (complications after a urinary tract infection)) were not considered to be related to omega‐3 PUFAs (<a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). </p> <p><a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> did not report adverse events or serious adverse events for each group. They described only the drop‐out rate as evenly distributed between the groups without unbundling the reasons. Reasons for overall group drop‐outs related to adverse events were diarrhoea (nine drop‐outs), dysphagia owing to the size of the capsules (nine drop‐outs) and new serious somatic disease (10 drop‐outs). We obtained no further detailed information regarding the distribution of these events to the groups by contacting Dr. Freund‐Levy by mail. </p> <p><a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> described adverse events at 18 months' follow‐up as diarrhoea (omega‐3 PUFAs: 7.6%; placebo: 6.1%), urinary tract infections (omega‐3 PUFAs: 9.7%; placebo: 7.3%), falls (omega‐3 PUFAs: 17.6%; placebo: 20.1%), dizziness (omega‐3 PUFAs: 5.0%; placebo: 5.5%) and agitation (omega‐3 PUFAs: 10.1%; placebo: 7.3%). Almost every participant had an adverse event when these outcomes were combined (omega‐3 PUFAs: 89.9%; placebo: 87.8%) (RR 1.02, 95% CI 0.95 to 1.10; 402 participants; 1 study). The distribution of "any adverse events" was similar between the treatment and the placebo group (<a href="./references#CD009002-fig-0014" title="">Analysis 1.8</a>). </p> <p>Serious adverse events were infrequent and the differences between the groups did not reach statistical significance (at the 5% level). Participants in the omega‐3 PUFAs group were more than twice as likely to die (omega‐3 PUFAs: 4.6%; placebo: 2.4%) or to develop a deep venous thrombosis or pulmonary embolus (omega‐3 PUFAs: 3.4%; placebo: 1.2%). Hospitalisation was a further reported serious adverse event (omega‐3 PUFAs: 28.2%; placebo: 26.2%). Considering all serious adverse events (death, hospitalisation, prolongation of hospitalisation and life‐threatening incidents) together, there was no difference between groups (RR 1.05, 95% CI 0.78 to 1.41; 402 participants; 1 study) (<a href="./references#CD009002-fig-0015" title="">Analysis 1.9</a>). We graded the quality of evidence for serious adverse events as high as we do not assume measurement errors for the included outcomes as likely. We downgraded the quality of evidence for the outcome 'any adverse events' for measurement uncertainties because the outcome was an accumulation of partial subjective outcomes (i.e. dizziness) and it was not clear how they were measured (<a href="./full#CD009002-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Compliance was not explicitly reported in any of the trials and can be merely assumed by DHA levels presented in all three trials showing significant increases in the interventions groups but not in the placebo groups (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>; <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). </p> </section> <section id="CD009002-sec-0099"> <h4 class="title">Symptoms associated with dementia (secondary outcome)</h4> <p>Mental health was depicted within the trials as depressive symptoms (MADRS) and neuropsychiatric disturbances (NPI). The ADCS trial used a 12‐item version of the NPI (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>), and the OmegAD trial used an extended version (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>). The meta‐analysis of both trials results revealed no difference at six months (SMD 0.10, 95% CI ‐0.07 to 0.27; 543 participants; 2 studies; I<sup>2</sup> = 0%) (<a href="./references#CD009002-fig-0012" title="">Analysis 1.6</a>). We judged the quality of evidence across the studies as high (<a href="./full#CD009002-tbl-0001">summary of findings Table for the main comparison</a>). Considering missing data in an LME model, there was no difference observed in the ADCS trial at 18 months (P value = 0.11) (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). </p> <p>Only <a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> measured the severity of depressive episodes using the MADRS. However, the means of both groups were very low indicating no relevant depressive symptoms. There was no significant difference between groups (MD ‐0.10, 95% CI ‐0.74 to 0.54; 178 participants) (<a href="./references#CD009002-fig-0013" title="">Analysis 1.7</a>). The quality of evidence was high (<a href="./full#CD009002-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD009002-sec-0100"> <h4 class="title">Quality of life (secondary outcome)</h4> <p>The ADCS trial assessed QoL using participant‐reported and proxy‐reported by partners or carers QoL‐AD. Dr. Quinn provided us with unpublished data from both. In this trial, there was no difference when QoL was assessed by participants at six months (MD ‐0.10, 95% CI ‐1.28 to 1.08; 332 participants) (<a href="./references#CD009002-fig-0016" title="">Analysis 1.10</a>) (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). We judged the quality of the evidence at six months' follow‐up as high. There was a difference in favour for placebo when QoL was assessed using informant‐rated scores at six months (MD ‐1.76, 95% CI ‐3.04 to ‐0.48; 331 participants) (<a href="./references#CD009002-fig-0017" title="">Analysis 1.11</a>). Both results remained similar at 18 months (see <a href="./references#CD009002-fig-0018" title="">Analysis 1.12</a> and <a href="./references#CD009002-fig-0019" title="">Analysis 1.13</a>). We downgraded the quality of evidence for QoL rated by participants at 18 months because of substantial group differences in the follow‐up (<a href="./full#CD009002-tbl-0001">summary of findings Table for the main comparison</a>). We judged the rating of QoL by the participants themselves as more trustworthy than a proxy measurement. Therefore, we do not present the proxy measure of QoL in <a href="./full#CD009002-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>Considering missing data in LME models, there was no difference at 18 months, whether QoL was participant‐rated (P value = 0.66) or informant‐rated (P value = 0.41) (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). </p> </section> <section id="CD009002-sec-0101"> <h4 class="title">Effects on subgroups</h4> <p>The data were not sufficient to perform our pre‐defined subgroup analyses by dementia stage and nutrition status. </p> <p><a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> conducted several subgroup ITT analyses (LME) of a more exploratory character (no adjustment for multiple testing and reduced power to detect a difference). There were no differences for any outcomes in subgroups based on higher and lower baseline MMSE scores (cut‐off: 21 score points) and CDR (cut‐off: 0.5, 1.0 and 2.0 score points). Further subgroup analyses reported in <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> and <a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> were not pre‐defined in our protocol, therefore we have not included them in our review. </p> </section> <section id="CD009002-sec-0102"> <h4 class="title">Sensitivity analysis</h4> <p>We assumed that the means and SDs of the outcomes for missing participants in both groups corresponded with the values for observed cases in the control group. We imputed missing six‐month values for ADAS‐Cog in all three trials (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>; <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>; <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a>). The meta‐analysis based on this assumption showed no difference between the groups on ADAS‐Cog (SMD ‐0.02, 95% CI ‐0.18 to 0.13; 632 participants; 3 studies; I<sup>2</sup> = 0%) (<a href="./references#CD009002-fig-0020" title="">Analysis 1.14</a>) (see <a href="#CD009002-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD009002-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Omega‐3 PUFA versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Sensitivity analysis 1.15 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog; 6 months' follow‐up, imputed means for missing data. Assumption: values of missing data = values of control group). LOCF: last observation carried forward; PP: per protocol." data-id="CD009002-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Omega‐3 PUFA versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Sensitivity analysis 1.15 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog; 6 months' follow‐up, imputed means for missing data. Assumption: values of missing data = values of control group). LOCF: last observation carried forward; PP: per protocol. </p> </div> </div> </div> <p>We also combined MMSE and ADAS‐Cog results at endpoint from all three trials, irrespective of study duration. In these analyses, there was no significant difference between groups for MMSE (MD 0.55, 95% CI ‐0.31 to 1.40; 464 participants; 3 studies; I<sup>2</sup> = 0%) (<a href="./references#CD009002-fig-0021" title="">Analysis 1.15</a>) or ADAS‐Cog (SMD ‐0.03, 95% CI ‐0.20 to 0.15; 504 participants; 3 studies; I<sup>2</sup> = 0%) (<a href="./references#CD009002-fig-0022" title="">Analysis 1.16</a>). <a href="#CD009002-fig-0006">Figure 6</a> shows the sensitivity analysis for MMSE. </p> <div class="figure" id="CD009002-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Omega‐3 versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Sensitivity analysis 1.19 Mini‐Mental State Examination (MMSE; 6, 12 and 18 months' follow‐up, per protocol (PP) analysis)." data-id="CD009002-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Omega‐3 versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Sensitivity analysis 1.19 Mini‐Mental State Examination (MMSE; 6, 12 and 18 months' follow‐up, per protocol (PP) analysis). </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009002-sec-0103" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009002-sec-0103"></div> <section id="CD009002-sec-0104"> <h3 class="title" id="CD009002-sec-0104">Summary of main results</h3> <p>The review included three studies involving 632 participants with AD.</p> <p>There was no convincing benefit of omega‐3 PUFAs for our pre‐defined primary outcomes of cognition, function or dementia severity, or for any other outcomes within the scope of this review, regardless of the dose of omega‐3 PUFAs or the duration of intake. There was a numerical advantage of omega‐3 PUFAs for cognition but even the upper boundaries of the related CIs were nearly always below published estimates of an MCID. Our results on the safety and adverse effects of dietary omega‐3 PUFAs were consistent with previous findings and assumptions (<a href="./references#CD009002-bbs2-0033" title="European Food Safety Authority (EFSA). Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). EFSA Journal2012;10(7):2815. [DOI: 10.2903/j.efsa.2012.2815] ">EFSA 2012</a>; <a href="./references#CD009002-bbs2-0037" title="EritslandJ . Safety considerations of polyunsaturated fatty acids. American Journal of Clinical Nutrition2000;71(Suppl):197S‐201S. ">Eritsland 2000</a>; <a href="./references#CD009002-bbs2-0038" title="Food , Agriculture Organization of the United Nations(FAO) . Fats and fatty acids in human nutrition. Report of an expert consultation. 10‐14 November 2008, Geneva. FAO Food and Nutrition Paper 91. Rome, 2010:188. [ISBN 978‐92‐5‐106733‐8] ">FAO 2010</a>; <a href="./references#CD009002-bbs2-0089" title="SydenhamE , DangourAD , LimW‐S . Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005379.pub3] ">Sydenham 2012</a>). There were adverse events in the study population, but these occurred equally in the treatment and the placebo groups. </p> </section> <section id="CD009002-sec-0105"> <h3 class="title" id="CD009002-sec-0105">Overall completeness and applicability of evidence</h3> <p>All trials assessed relevant endpoints to evaluate therapeutic efficacy in people with dementia. The larger studies addressed cognitive function, ADL and global severity of dementia together (<a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a>; <a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>), as recommended by an expert group of the European Medicines Agency (<a href="./references#CD009002-bbs2-0035" title="European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. EMA/CHMP/539931/2014 Corr. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176827.pdf (accessed 23 October 2014). ">EMA 2014</a>). However, the pilot study of <a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> addressed a surrogate parameter as the primary endpoint and the study was not designed to test efficacy in the secondary endpoints relevant for this review. </p> <p>All trials included participants with diagnoses of AD of mild to moderate severity and tested an appropriate dose (according to <a href="./references#CD009002-bbs2-0032" title="EFSA Panel on DieteticProducts , Nutrition , Allergies(NDA) . Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal2010;8(3):1461. [DOI: 10.2903/j.efsa.2010.1461] ">EFSA 2010</a>; <a href="./references#CD009002-bbs2-0033" title="European Food Safety Authority (EFSA). Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). EFSA Journal2012;10(7):2815. [DOI: 10.2903/j.efsa.2012.2815] ">EFSA 2012</a>). We found no trial investigating omega‐3 PUFAs in other dosages, or type or stage of dementia. Therefore, we cannot draw conclusions on people with VaD, DLB, PDD or FTD, or more severe forms of AD. Mean values of nutritional parameters presented in the studies indicated no malnutrition or lack of DHA at baseline and none of the trials investigated relevant subgroups. Therefore, we cannot rule out that trial participants with poorer baseline nutritional status may benefit more from the intervention. </p> </section> <section id="CD009002-sec-0106"> <h3 class="title" id="CD009002-sec-0106">Quality of the evidence</h3> <p>All three studies were RCTs. By using the GRADE approach, we rated the overall quality of evidence for most outcomes as high. By the GRADE definition, this means, "we are very confident that the true effect lies close to that of the estimate of the effect" (<a href="./references#CD009002-bbs2-0087" title="SchünemannH , BrożekJ , GuyattG , OxmanA (editors) . GRADE handbook for grading quality of evidence and strength of recommendations. Chapter 5. Updated October 2013. gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html (accessed 31 March 2016). ">Schünemann 2013</a>). However, <a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> did not report if blinding was maintained long enough to blind the outcome assessor but we assumed that this was a reporting issue and judged that the possible impact on the pooled outcomes was small when combined with the larger ADCS trial (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>). All uncertainties regarding data that arose during the review process were resolved when we contacted the study authors. </p> </section> <section id="CD009002-sec-0107"> <h3 class="title" id="CD009002-sec-0107">Potential biases in the review process</h3> <p>More than one‐quarter of all randomised participants discontinued study participation. To date, there is no optimal method to address missing data in trials on dementia. Due to the progressive course of the disease, both ITT based on the LOCF data and per‐protocol analysis based on data assessed on completers of the trials are questionable, if not inappropriate, analysis methods (<a href="./references#CD009002-bbs2-0035" title="European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. EMA/CHMP/539931/2014 Corr. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176827.pdf (accessed 23 October 2014). ">EMA 2014</a>). We addressed this potential bias in a six‐month sensitivity analysis, imputing missing data on the assumption of similarity to the data of the control group and the results remained similar. However, it is conceivable that this assumption is violated by the possibility that participants who discontinued the studies could have had even worse results than the control groups. </p> </section> <section id="CD009002-sec-0108"> <h3 class="title" id="CD009002-sec-0108">Agreements and disagreements with other studies or reviews</h3> <p>This review is in line with several other Cochrane systematic reviews investigating the effect of omega‐3 PUFAs in the prevention or therapy of neurological diseases (<a href="./references#CD009002-bbs2-0028" title="DennisCL , DowswellT . Interventions (other than pharmacological, psychosocial or psychological) for treating antenatal depression. Cochrane Database of Systematic Reviews. John Wiley &amp; Sons, Ltd, 2013; Vol. 7. [DOI: 10.1002/14651858.CD006795.pub3] ">Dennis 2013</a>; <a href="./references#CD009002-bbs2-0056" title="IrvingCB , Mumby‐CroftR , JoyLA . Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD001257.pub2] ">Irving 2006</a>; <a href="./references#CD009002-bbs2-0070" title="MontgomeryP , RichardsonAJ . Omega‐3 fatty acids for bipolar disorder. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005169.pub2] ">Montgomery 2008</a>, <a href="./references#CD009002-bbs2-0089" title="SydenhamE , DangourAD , LimW‐S . Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database of Systematic Reviews2012, Issue 6. [DOI: 10.1002/14651858.CD005379.pub3] ">Sydenham 2012</a>), where there was no evidence from RCTs for the effectiveness of omega‐3 PUFAs. This applies also for a range of other diseases affecting people of advanced age (<a href="./references#CD009002-bbs2-0022" title="CampbellA , PriceJ , HiattWR . Omega‐3 fatty acids for intermittent claudication. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003833.pub4] ">Campbell 2013</a>; <a href="./references#CD009002-bbs2-0047" title="HartwegJ , PereraR , MontoriVM , DinneenSF , HawnAN , FarmerAJ . Omega‐3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD003205.pub2] ">Hartweg 2008</a>; <a href="./references#CD009002-bbs2-0051" title="HooperL , ThompsonRL , HarrisonRA , SummerbellCD , MooreH , WorthingtonHV , et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD003177.pub2] ">Hooper 2004</a>; <a href="./references#CD009002-bbs2-0058" title="LawrensonJG , EvansJR . Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD010015.pub3] ">Lawrenson 2015</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009002-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009002-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009002-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Omega‐3 PUFAs versus placebo for mild to moderate Alzheimer's disease. Analysis 1.1 Mini‐Mental State Examination (MMSE; 6 months' follow‐up, PP analysis)." data-id="CD009002-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: Omega‐3 PUFAs versus placebo for mild to moderate Alzheimer's disease. Analysis 1.1 Mini‐Mental State Examination (MMSE; 6 months' follow‐up, PP analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Omega‐3 PUFAs versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Analysis 1.3 Activities of daily living (6 months' follow‐up, PP analysis). ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; DAD: Disability Assessment for Dementia." data-id="CD009002-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: Omega‐3 PUFAs versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Analysis 1.3 Activities of daily living (6 months' follow‐up, PP analysis). ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; DAD: Disability Assessment for Dementia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Omega‐3 PUFA versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Sensitivity analysis 1.15 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog; 6 months' follow‐up, imputed means for missing data. Assumption: values of missing data = values of control group). LOCF: last observation carried forward; PP: per protocol." data-id="CD009002-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: Omega‐3 PUFA versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Sensitivity analysis 1.15 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog; 6 months' follow‐up, imputed means for missing data. Assumption: values of missing data = values of control group). LOCF: last observation carried forward; PP: per protocol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Omega‐3 versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Sensitivity analysis 1.19 Mini‐Mental State Examination (MMSE; 6, 12 and 18 months' follow‐up, per protocol (PP) analysis)." data-id="CD009002-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: Omega‐3 versus placebo for mild to moderate Alzheimer's disease. Published and unpublished. Sensitivity analysis 1.19 Mini‐Mental State Examination (MMSE; 6, 12 and 18 months' follow‐up, per protocol (PP) analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 1 Mini‐Mental State Examination (MMSE; 6 months' follow‐up, per protocol (PP) analysis)." data-id="CD009002-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 1 Mini‐Mental State Examination (MMSE; 6 months' follow‐up, per protocol (PP) analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 2 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog; 6 months' follow‐up, PP analysis)." data-id="CD009002-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 2 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog; 6 months' follow‐up, PP analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 3 Activities of daily living (6 months' follow‐up, PP analysis)." data-id="CD009002-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 3 Activities of daily living (6 months' follow‐up, PP analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 4 Older Americans Resources and Services ‐ Instrumental Activities of Daily Living (OARS‐IADL) change scores (12 months' follow‐up, PP analysis)." data-id="CD009002-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 4 Older Americans Resources and Services ‐ Instrumental Activities of Daily Living (OARS‐IADL) change scores (12 months' follow‐up, PP analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 5 Clinical Dementia Rating ‐ Sum of Boxes (CDR‐SOB; 6 months' follow‐up, PP analysis)." data-id="CD009002-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 5 Clinical Dementia Rating ‐ Sum of Boxes (CDR‐SOB; 6 months' follow‐up, PP analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 6 Neuropsychiatric Inventory (NPI; 6 months' follow‐up, PP analysis)." data-id="CD009002-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 6 Neuropsychiatric Inventory (NPI; 6 months' follow‐up, PP analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 7 Montgomery‐Åsberg Depression rating scale (MADRS; 6 months' follow‐up, PP analysis)." data-id="CD009002-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 7 Montgomery‐Åsberg Depression rating scale (MADRS; 6 months' follow‐up, PP analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 8 Adverse events (18 months' follow‐up, intention‐to‐treat (ITT) analysis))." data-id="CD009002-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 8 Adverse events (18 months' follow‐up, intention‐to‐treat (ITT) analysis)). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 9 Any serious adverse events (18 months' follow‐up, ITT analysis)." data-id="CD009002-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 9 Any serious adverse events (18 months' follow‐up, ITT analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 10 Quality of Life Alzheimer's Disease scale (QoL‐AD; 6 months' follow‐up, PP analysis, participant rated)." data-id="CD009002-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 10 Quality of Life Alzheimer's Disease scale (QoL‐AD; 6 months' follow‐up, PP analysis, participant rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 11 QoL‐AD scale (6 months' follow‐up, PP analysis, informant rated)." data-id="CD009002-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 11 QoL‐AD scale (6 months' follow‐up, PP analysis, informant rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 12 QoL‐AD scale (18 months' follow‐up, PP analysis, informant rated)." data-id="CD009002-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 12 QoL‐AD scale (18 months' follow‐up, PP analysis, informant rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 13 QoL‐AD scale (18 months' follow‐up, PP analysis, participant rated)." data-id="CD009002-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 13 QoL‐AD scale (18 months' follow‐up, PP analysis, participant rated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-14.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 14 Sensitivity analysis ADAS‐Cog (6 months' follow‐up, imputed means for missing data. Assumption: values of missing data = values of control group)." data-id="CD009002-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 14 Sensitivity analysis ADAS‐Cog (6 months' follow‐up, imputed means for missing data. Assumption: values of missing data = values of control group). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-15.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 15 Sensitivity analysis MMSE (6, 12 and 18 months' follow‐up, PP analysis)." data-id="CD009002-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 15 Sensitivity analysis MMSE (6, 12 and 18 months' follow‐up, PP analysis). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009002-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/urn:x-wiley:14651858:media:CD009002:CD009002-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_t/tCD009002-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 16 Sensitivity analysis ADAS‐Cog (6 and 18 months' follow‐up)." data-id="CD009002-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 PUFAs versus placebo, Outcome 16 Sensitivity analysis ADAS‐Cog (6 and 18 months' follow‐up). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/media/CDSR/CD009002/image_n/nCD009002-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009002-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Omega‐3 PUFA supplements compared to placebo for people with mild to moderate Alzheimer's disease</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Omega‐3 PUFA supplements compared to placebo for people with mild to moderate Alzheimer's disease </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with mild to moderate Alzheimer's disease<br/> <b>Setting:</b> any setting<br/> <b>Intervention:</b> omega‐3 PUFA supplements<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo for mild to moderate Alzheimer's disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with omega‐3 PUFAs for mild to moderate Alzheimer's disease</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Any adverse event (combined: diarrhoea, urinary tract infection, falls, dizziness, agitations)<br/> Assessed with: unclear<br/> Follow‐up: mean 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>RR 1.02<br/> (0.95 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>402<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>‐</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>878 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>896 per 1000<br/> (834 to 966) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Moderate</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>878 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>896 per 1000<br/> (834 to 966) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Serious adverse events<br/> "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>) </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.05<br/> (0.78 to 1.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>402<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>305 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000<br/> (238 to 430) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL</p> <p>Assessed with: QoL‐AD scale rated by participant<br/> Scale from 13 to 52 (higher = better)<br/> Follow‐up: mean 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean QoL was 40.02 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in QoL in the intervention group was 0.39 scale points fewer (1.79 fewer to 1.01 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL<br/> Assessed with: QoL‐AD scale rated by participant<br/> Scale from 13 to 52 (higher = better)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean QoL was 39.86 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in QoL in the intervention group was 0.1 scale points fewer (1.28 fewer to 1.08 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>332<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental health (depression)<br/> Assessed with: MADRS<br/> Scale from 0 to 30 (lower = better)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean depression (MADRS) score was 1.6 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in depression (MADRS) score in the intervention group was 0.1 scale points fewer (0.74 fewer to 0.54 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental health</p> <p>Assessed with: NPI</p> <p>Follow‐up: mean 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean difference in mental health (NPI) score in the intervention group was 0.1 standard deviations more (0.07 fewer to 0.27 more) <sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cognitive function<br/> Assessed with: ADAS‐Cog (different versions)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean difference in global cognitive function (ADAS‐Cog) in the intervention group was 0.02 standard deviations fewer (0.19 fewer to 0.15 more) 4 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>566<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Global cognitive function<br/> assessed with: MMSE scale<br/> Scale from 0 to 30 (higher = better)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean global cognitive function ranged from 20.4 to 22.4 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in global cognitive function (MMSE) in the intervention group was 0.18 scale points more (1.05 fewer to 1.41 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IADL<br/> Assessed with: OARS‐IADL<br/> Scale from 0 to 14 (lower = better)<br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in score for IADL was 4.2 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in the change in score for IADL in the intervention group was 3.5 scale points lower (4.3 lower to 2.7 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADL<br/> Assessed with: DAD and ADCS‐ADL<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The mean difference in ADL in the intervention group was 0.02 standard deviations fewer (0.19 fewer to 0.16 more)<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>544<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall dementia severity (cognition and function combined)<br/> Assessed with: CDR‐SOB<br/> Scale from 0 to 18 (lower = better)<br/> Follow‐up: mean 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean overall dementia severity (CDR‐SOB score) ranged from 6.5 to 6.75 scale points</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean difference in overall dementia severity (CDR‐SOB score) in the intervention group was 0 scale points (0.58 fewer to 0.57 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>542<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ADAS‐Cog:</b> Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; <b>ADCS‐ADL:</b> Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; <b>ADL:</b> activities of daily living; <b>CDR‐SOB:</b> Clinical Dementia Rating ‐ Sum of Boxes; <b>CI:</b> confidence interval; <b>DAD:</b> Disability Assessment for Dementia; <b>IADL:</b> instrumental activities of daily living; <b>NPI:</b> Neuropsychiatric Inventory; <b>MADRS:</b> Montgomery‐Åsberg Depression Rating Scale; <b>MMSE:</b> Mini‐Mental State Examination; <b>OARS‐IADL:</b> Older Americans Resources and Services ‐ Instrumental Activities of Daily Living; <b>OR:</b> odds ratio; <b>PUFA:</b> polyunsaturated fatty acid; <b>QoL:</b> quality of life; <b>QoL‐AD:</b> Quality of Life Alzheimer's Disease; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to serious risk of bias: combined outcome (i.e. diarrhoea, falls, agitation) that includes outcomes of unclear measurement methods (i.e. dizziness). </p> <p><sup>2</sup> Downgraded one level due to serious risk of bias: follow‐up differed between groups: 63.0% (omega‐3 PUFAs) and 72.6% (placebo). </p> <p><sup>3</sup> Downgraded one level due to serious imprecision: wide CI; only 22 participants overall. </p> <p><sup>4</sup> SMD presented in place of absolute values in the intervention and comparison groups as studies used the different scale versions. </p> <p><sup>5</sup> SMD presented in place of absolute values in the interventions and comparison groups as studies used different scales to measure the same construct. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Omega‐3 PUFA supplements compared to placebo for people with mild to moderate Alzheimer's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009002-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Methods used to control bias resulting from conflict of interest</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Beforehand published primary outcomes presented?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Planning phase and funding: role of industry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conducting phase: role of industry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Analysing process: role of industry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting process: role of industry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Overall judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The OmegAD study was funded in part by Pronova Biocare A/S, Lysaker, Norway. This company was represented in the trial steering committee for study design and the decision to submit for publication, and provided the EPAX1050TG and placebo preparations; however, the company was not involved in collection, analyses, or interpretation of the data" p. 1408 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The funding company provided the intervention and placebo preparations.</p> <p>"[...] the company was not involved in collection, analyses, or interpretation of the data" p. 1408 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"[...] the company was not involved in collection, analyses, or interpretation of the data" p. 1408 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The funding company was in involved in the decision to submit for publication. It was not part of the author team. </p> <p>1 author has received travel<br/> grants from Pronova Biocare A/S </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> <p>Rationale: data collection, analysis, presentation and interpretation seem not to be influenced by the manufacturer itself or other undue interests </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 employees of Martek Biosciences (manufacturers of DHA and inventor of a patent for DHA for treatment of AD) were involved in study concept and design </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 employees of Martek Biosciences were involved in administrative, technical or material support </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Martek employees participated in design of the study and in revision of the manuscript ("Irish Endocrine Society 34th Annual Meeting,") The statistical analysis was conducted by the Alzheimer's Disease Cooperative Study Data Core. Martek employees did not participate in the statistical analysis and did not have access to the data prior to the completion of data analysis" p. 9 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 Martek employees were involved in the critical revision of the manuscript for important intellectual content. </p> <p>2 other authors were (since 2010) co‐inventors on a patent for DHA for the treatment of AD, which was filed in 2009; both waived personal rights to royalties related to this patent. Both were involved in study design and concept, supervision and acquisition of data. 1 was additionally involved in administrative, technical or material support. 1 drafted the manuscript the other was involved in its critical revision </p> <p>No other authors reported disclosures.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low</p> <p>Rationale: some trial authors disclosed industry financial ties or employment in detail. However, we received all data that we had asked for and the results of the primary endpoints were reported as planned in the trials registration form. The study was otherwise accompanied by external experts and the statistical analysis seemed to be conducted independently from manufactures employees </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>The study design was "approved by an oversight committee of the National Institute on Aging. Representatives from the National Institute on Aging participated in meetings of the steering committee of the Alzheimer's Disease Cooperative Study during the course of the trial" p. 9 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nordic Natural, Watsonville, CA, USA, supplied the fish oil and placebo oil, and Meda Pharma, Bad Homburg </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 from 11 authors disclosed fees for consultancy or lectures</p> <p>1 author was also involved in the ADCS‐NIA trial. He stated in the related article (<a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a>) that he was co‐inventor on a patent for DHA for the treatment of AD but waived personal rights to royalties related to this patent </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> <p>Rationale: the study was well reported, we received all data requested and we judged the financial ties to the manufacturer as marginally </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>AD: Alzheimer's disease; ADCS‐NIA: Alzheimer's Disease Cooperative Study ‐ National Institute on Aging; DHA: docosahexaenoic acid. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Methods used to control bias resulting from conflict of interest</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009002-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of participants and main interventions of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnosis and severity of disease</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age (SD) (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean MMSE (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean BMI (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Use of AD medicine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily omega‐3 dose / treatment duration</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes relevant to this review</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0001" title="EriksdotterM , FalahatiF , VedinI , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Effects of omega‐3 fatty acid supplementation on plasma fatty acids, gender effects, and effects on cognition in Alzheimer's patients: the OmegAD study. Alzheimer's &amp; Dementia2014;40(4 Suppl):P455. EriksdotterM , VedinI , FalahatiF , Freund‐LeviY , HjorthE , Faxen‐IrvingG , et al. Plasma fatty acid profiles in relation to cognition and gender in Alzheimer's disease patients during oral omega‐3 fatty acid supplementation: the OmegAD study. Journal of Alzheimer's Disease2015;48(3):805‐12. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the Omega‐3 Alzheimer's Disease study. Journal of the American Geriatrics Society2009;57:11‐7. Faxen‐IrvingG , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , HjorthE , PalmbladJ , et al. Effects on transthyretin in plasma and cerebrospinal fluid by DHA‐rich n ‐ 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's disease2013;36:1‐6. Freund‐LeviY , BasunH , CederholmT , Faxen‐IrvingG , GarlindA , GrutM , et al. Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry2008;23:161‐9. Freund‐LeviY , CederholmT , BasuS . Oxidative stress and cox‐mediated inflammation in patients with Alzheimer's disease and effects of N‐3 fatty acid supplementation the omegAD study. Clinical Nutrition2011;Suppl:9. Freund‐LeviY , HjorthE , LindbergC , CederholmT , Faxen‐IrvingG , VedinI , et al. Effects of omega‐3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dementia and Geriatric Cognitive Disorders2009;27:481‐90. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , Eriksdotter JonhagenM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. Freund‐LeviY , VedinI , CederholmT , BasunH , Faxen IrvingG , EriksdotterM , et al. Transfer of omega‐3 fatty acids across the blood‐brain barrier after dietary supplementation with a docosahexaenoic acid‐rich omega‐3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. Journal of Internal Medicine2014;275:428‐36. Freund‐LeviY , VedinI , HjorthE , BasunH , IrvingGF , SchultzbergM , et al. Effects of supplementation with omega‐3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. Journal of Alzheimer's Disease2014;42:823‐31. Freund‐Levi , Y , Eriksdotter‐Jonhagen , M , Cederholm , T , Basun , H , Faxen‐Irving , G , Garlind , et al. Omega‐3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study ‐ a randomized double‐blind trial. Archives of Neurology2006; Vol. 63, issue 10:1402‐8. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , BrismarK , HjorthE , et al. Omega‐3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega‐3 Alzheimer's disease study [erratum appears in Journal of the American Geriatrics Society 2009;57(3):579]. Journal of the American Geriatrics Society2009;57:11‐7. IrvingGF , Freund‐LeviY , Eriksdotter‐JonhagenM , BasunH , PalmbladJ , VedinI , et al. N‐3 fatty acid treatment and plasma transthyretin in patients with Alzheimer's disease. FASEB Journal2009;23:Suppl 543.10. Levi FreundY , VedinI , CederholmT , BasunH , Irving FaxenG , Jönhagen EriksdotterM , et al. Effects of a DHA rich omega‐3 fatty acid supplementation for Alzheimer disease patients on fatty acid composition in cerebrospinal fluid, disease biomarkers and cognition: the OmegAD study. Journal of Molecular Neuroscience2012;48:S36. PalmbladJ . Effects of a DHA rich omega‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid and relation to Alzheimer disease. The OmegAD study. Clinical Nutrition2011;Suppl:117‐8. VedinI , CederholmT , Freund LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of docosahexaenoic acid‐rich n‐3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study. American Journal of Clinical Nutrition2008;87:1616‐22. VedinI , CederholmT , Freund‐LeviY , BasunH , GarlindA , IrvingGF , et al. Effects of DHA‐rich n‐3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study. PLoS One2012;7:e35425. VedinI , CederholmT , Freund‐LeviY , BasunH , HjorthE , IrvingGF , et al. Reduced prostaglandin F‐2 alpha release from blood mononuclear leukocytes after oral supplementation of omega 3 fatty acids: the OmegAD study. Journal of Lipid Research2010;51:1179‐85. VedinI , Freund LeviY , CederholmT , BasunH , HjorthE , IrvingGF , et al. Effects of a DHA rich n‐3 fatty acid supplementation on fatty acid composition in cerebrospinal fluid in Alzheimer disease. The OmegAD study. FASEB Journal2013;27:lb343. WangX , HjorthE , VedinI , EriksdotterM , Freund‐LeviY , WahlundLO , et al. Effects of n‐3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study. Journal of Lipid Research2015;56(3):674‐81. ">Freund‐Levi 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total 204</p> <p>IG 103</p> <p>CG 101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD</p> <p>mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.47 (8.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.41 (3.8)</p> <p>(PP population)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.37 (3.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100% cholinesterase inhibitors</p> <p>Memantine not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHA 1.7 g + EPA 0.6 g</p> <p>26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog</p> <p>MMSE</p> <p>CDR‐SOB</p> <p>NPI</p> <p>DAD</p> <p>MADRS</p> <p>Safety and tolerability</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0002" title="QuinnJ . Alzheimer's Disease Cooperative Study DHA primary analysis. Individual patient data (as supplied 22 May 2015). Data on file. QuinnJ . Effects of docosahexaenoic acid (DHA) in slowing the progression of Alzheimer's disease. Neuropsychopharmacology2006;31:S1‐69. QuinnJ , ShintoL , Yurko‐MauroK , GalaskoD , AisenP , MontineT . Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease. Alzheimer's &amp; Dementia2012;8(4):P585. QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. [DOI: 10.1001/jama.2010.1510] ">Quinn 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>402</p> <p>IG 238</p> <p>CG 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD</p> <p>mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (8.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.66 (3.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (4.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.8% cholinesterase inhibitors</p> <p>60.4% memantine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHA 900‐1100 mg</p> <p>18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog</p> <p>CDR‐SOB</p> <p>MMSE</p> <p>ADCS‐ADL</p> <p>QoL</p> <p>NPI</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009002-bbs2-0003" title="ShintoL . Unpublished six months results. Individual patient data (as supplied 16 July 2015). Data on file. ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardaW , Baldauf‐WagneraS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimers Disease2014; Vol. 38, issue 1. ">Shinto 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> <p>IG 13</p> <p>CG 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>AD</p> <p>mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.55 (9.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.45 (2.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (3.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.61% cholinesterase inhibitors or memantine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>675 mg DHA</p> <p>+ 975 mg EPA</p> <p>12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog</p> <p>MMSE</p> <p>OARS‐ADL</p> <p>OARS‐IADL</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AD: Alzheimer's disease; ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; BMI: body mass index; CDR‐SOB: Clinical Dementia Rating ‐ Sum of Boxes; CG: control group; DAD: Disability Assessment for Dementia; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; IG: intervention group; MADRS: Montgomery‐Åsberg Depression rating scale; MMSE: Mini‐Mental State Examination; NPI: Neuropsychiatric Inventory; OARS‐ADL: Older Americans Resources and Services ‐ Activities of Daily Living; OARS‐IADL: Older Americans Resources and Services ‐ Instrumental Activities of Daily Living; PP: per protocol; QoL: quality of life; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics of participants and main interventions of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009002-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Prioritisation of outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcome (measurement in trials)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>People with AD (n = 14)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Relatives (n = 12)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Staff members (n = 11)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total (n = 37)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Importance for decision‐making</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Range</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects of medication (number of adverse events; number of serious adverse events) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.71 (8.71)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.75 (1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.91 (2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.16 (1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (QoL‐AD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.57 (2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.33 (1.23)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.09 (1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.97 (1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mental health (MADRS; NPI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.79 (1.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.00 (0.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.00 (1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.92 (1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>General cognition (ADAS‐Cog; MMSE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.21 (1.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.08 (1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.36 (2.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.92 (1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory (not measured)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.86 (1.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.08 (1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.00 (2.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.35 (1.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complex activities of daily living (i.e. shopping) (OARS‐IADL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.14 (1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.82 (1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.09 (1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.33 (1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Simple activities of daily living (i.e. dressing) (ADCS‐ADL; DAD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.71 (3.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.00 (2.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.82 (1.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.81 (2.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined cognition and function (CDR‐SOB)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; CDR‐SOB: Clinical Dementia Rating ‐ Sum of Boxes; DAD: Disability Assessment for Dementia; MADRS: Montgomery‐Åsberg Depression rating scale; MMSE: Mini‐Mental State Examination; n: number of participants; NPI: Neuropsychiatric Inventory; OARS‐IADL: Older Americans Resources and Services ‐ Instrumental Activities of Daily Living; QoL‐AD: Quality of Life Alzheimer's Disease; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Prioritisation of outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009002-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Unpublished data from the ADCS trials (total scores, provided via personal communication)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Measurement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Baseline</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>6 months' follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>18 months' follow‐up</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Linear mixed‐effects model at 18 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Omega‐3 PUFA mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p><b>mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Omega‐3 PUFA</b> </p> <p><b>mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> <p><b>mean (SD)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Omega‐3 PUFA</b> </p> <p><b>mean (SD)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.96 (9.21)</p> <p>n = 162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.77 (8.87)</p> <p>n = 236</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.73<br/> (10.7) </p> <p>n = 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.53<br/> (11.07) </p> <p>n = 217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.53<br/> (14.57)<br/> n = 128 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.17<br/> (14.76) </p> <p>n = 175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADCS‐ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.68 (12.9)</p> <p>n= 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.12 (12.32)</p> <p>n = 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.8<br/> (15.43) </p> <p>n = 147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.55<br/> (14.94) </p> <p>n = 219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDR‐SOB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.77<br/> (2.61) </p> <p>n = 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.61 (2.62)</p> <p>n = 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.75<br/> (3.16) </p> <p>n = 148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.86<br/> (3.3) </p> <p>n = 216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NPI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.15 (10.83)</p> <p>n = 164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.92 (10.37)</p> <p>n = 238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.58</p> <p>(10.8)</p> <p>n = 146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.17</p> <p>(12.47)</p> <p>n = 219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL‐AD informant rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.96 (6.13)</p> <p>n = 151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.45 (5.78)</p> <p>n = 220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.31 (5.82)</p> <p>n = 136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.55 (5.84)</p> <p>n = 195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.91 (6.3)</p> <p>n = 120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.42 (5.95)</p> <p>n = 162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>QoL‐AD participant rated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.43 (5.38)</p> <p>n = 150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0 (4.84)</p> <p>n = 222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.86 (5.41)</p> <p>n = 133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.76 (5.33)</p> <p>n = 199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.02 (6.09)</p> <p>n = 119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.63 (5.45)</p> <p>n = 150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value = 0.66</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; CDR‐SOB: Clinical Dementia Rating ‐ Sum of Boxes; n: number of participants; NPI: Neuropsychiatric Inventory; PUFA: polyunsaturated fatty acid; QoL‐AD: Quality of Life Alzheimer's Disease; SD: standard deviation. </p> <p><sup>a</sup>For ADAS‐Cog missing items imputed with last observation carried forward; missing total scores not imputed. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Unpublished data from the ADCS trials (total scores, provided via personal communication)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009002-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Unpublished data as provided via personal communication by Dr. Shinto</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Measurement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>6 months' follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo mean (SD) n = 11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Omega mean (SD) n = 12</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADAS‐Cog</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.10 (6.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.8 (9.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.4 (4.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.9 (4.4)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; MMSE: Mini‐Mental State Examination; n: number of participants; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Unpublished data as provided via personal communication by Dr. Shinto</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/full#CD009002-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009002-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Omega‐3 PUFAs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mini‐Mental State Examination (MMSE; 6 months' follow‐up, per protocol (PP) analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐1.05, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Alzheimer's Disease Assessment Scale ‐ Cognitive subscale (ADAS‐Cog; 6 months' follow‐up, PP analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>566</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.19, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Activities of daily living (6 months' follow‐up, PP analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.19, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Older Americans Resources and Services ‐ Instrumental Activities of Daily Living (OARS‐IADL) change scores (12 months' follow‐up, PP analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinical Dementia Rating ‐ Sum of Boxes (CDR‐SOB; 6 months' follow‐up, PP analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.58, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Neuropsychiatric Inventory (NPI; 6 months' follow‐up, PP analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>543</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.07, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Montgomery‐Åsberg Depression rating scale (MADRS; 6 months' follow‐up, PP analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse events (18 months' follow‐up, intention‐to‐treat (ITT) analysis)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Any serious adverse events (18 months' follow‐up, ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Quality of Life Alzheimer's Disease scale (QoL‐AD; 6 months' follow‐up, PP analysis, participant rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 QoL‐AD scale (6 months' follow‐up, PP analysis, informant rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 QoL‐AD scale (18 months' follow‐up, PP analysis, informant rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 QoL‐AD scale (18 months' follow‐up, PP analysis, participant rated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Sensitivity analysis ADAS‐Cog (6 months' follow‐up, imputed means for missing data. Assumption: values of missing data = values of control group) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.18, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Sensitivity analysis MMSE (6, 12 and 18 months' follow‐up, PP analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [‐0.31, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Sensitivity analysis ADAS‐Cog (6 and 18 months' follow‐up) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.20, 0.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Omega‐3 PUFAs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009002.pub3/references#CD009002-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009002.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009002-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009002-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009002-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009002-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD009002-note-0006">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD009002-note-0004">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD009002-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009002-note-0008">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009002-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD009002-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009002\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009002\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009002\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009002\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009002\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jiwTpTuf&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009002.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009002.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009002.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009002.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009002.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725263238"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009002.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725263242"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009002.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e76f8597b936e',t:'MTc0MDcyNTI2My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 